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Summary
The maintenance of pluripotency in embryonic stem cells (ESC) is
regulated by a network of chromatin-associated proteins coordinated
by three master transcription factors Oct4, Sox2 and Nanog. To un-
derstand how different states of pluripotency are established, I devel-
oped three methods for studying chromatin-associated proteins glob-
ally, protein-targeted and locus-targeted in mouse ESC.
Firstly, to study chromatin protein composition in a global manner,
for the first time I developed in-vitro enzymatic labeling of chromatin
by biotinylated nucleotides using Terminal deoxynucleotidyltransferase
(TdT). As a result, more than 5000 proteins were significantly en-
riched in mouse ESCs in comparison to the negative control omitting
the biotinylation step. In addition to the canonical chromatin-binding
proteins, SICAP suggests chromatin association of some unexpected
proteins such as Fgf4, which is a growth factor. This observation was
further verified by immuno-staining.
Secondly, I combined SICAP with chromatin immuno-precipitation
(ChIP-SICAP) to identify proteins that interact with a target protein
specifically on chromatin. Using endogenous Oct4, Sox2 and Nanog
(OSN) as the targets of ChIP-SICAP, I identified about 400 proteins,
as the overlap of the three assays. These 400 proteins include a large
number of established interaction partners of the target proteins known
to participate in the core pluripotency network (e.g. Rex1, Prdm14,
Tcf3, Sall4, Esrrb, Tbx3, Stat3 etc). To reveal the co-localization sites
with OSN, I selected Trim24. Interestingly, using ChIP-seq it turned
out that Trim24 co-localizes with OSN on many super-enhancers of
pluripotency.
Thirdly, I developed a method to identify proteins bound to the
Nanog promoter using biotinylated oligonucleotides. The specificity of
the method, called targeted isolation of genomic regions (TIGR), was
validated using qPCR and high-throughput sequencing. Hence, several
proteins have been identified that are known to bind to, and regulate
transcriptional activity of Nanog. Comparing the meta-stable and the
ground-state of pluripotency, TIGR identified several nucleoporins that
associate with the Nanog promoter preferentially in the ground-state
of pluripotency. Using ChIP-qPCR I could validate the association of
Nup98 to the Nanog promoter.
Taken together, the data generated by the aforementioned methods
expand the circuitry of pluripotency, and shed a new light on the differ-
ences between the ground-state and meta-stable state of pluripotency.
Additionally, the newly developed methods are highly generalizable
and independent of cell culture or genetic engineering so that they can
be used for studying diverse biological systems.
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Zusammenfassung
Die Pluripotenz in embryonalen Stammzellen (ESC) wird durch ein komplexes
Netzwerk von Chromatin-assoziierten Proteinen aufrecht erhalten, das von den drei
Master-Transkriptionsfaktoren Oct4, Sox2 und Nanog kontrolliert wird. Um zu ver-
stehen, auf welche Weise verschiedene Zustände der Pluripotenz etabliert werden,
habe ich drei unterschiedliche, einander komplementäre Methoden zur Untersu-
chung von Chromatin-assoziierten Proteinen entwickelt: 1) Analyse auf globaler
Ebene, 2) in Bezug auf bestimmte Proteine und 3) in Bezug auf bestimmte Gen-
Loci in Maus-ESCs.
Im ersten Ansatz zur Charakterisierung der Gesamtheit der Chromatin-assozierten
Proteine auf globaler Ebene, entwickelte ich die erste beschriebene Methode zur
in vitro enzymatischen Markierung von Chromatin durch biotinylierte Nukleotide
unter Verwendung des Enzyms Terminal Desoxynukleotidyltransferase (TdT) (SI-
CAP). Als Ergebnis wurden mehr als 5,000 Proteine als signifikant in Maus ESCs
angereichert identifiziert, im Vergleich zur Negativkontrolle ohne Biotinylierungs-
schritt. Zusätzlich zu den kanonischen Chromatin-bindenden Proteinen, ergab die
SICAP Methode Chromatin-Assoziierung für einige unerwartete Proteine wie z.B.
den Wachstumsfaktor Fgf4. Diese Beobachtung konnte durch Immunfärbung bestä-
tigt werden.
Im zweiten Ansatz kombinierte ich die SICAP Methode mit Chromatin Immun-
präzipitation (ChIP- SICAP), um Proteine spezifisch zu identifizieren, die mit einem
Zielprotein an Chromatin wechselwirken. Die jeweils unabhängige Verwendung en-
dogener Oct4, Sox2 und Nanog (OSN) Proteine als Zielproteine für ChIP-SICAP
ergab die Identifizierung von etwa 400 Proteinen, die in allen drei Tests gemeinsam
detektiert wurden. Diese 400 Proteine umfassten eine große Anzahl von etablier-
ten Interaktionspartnern, die bekanntermaßen Teil des Pluripotenz-Netzwerks sind
(z.B. Rex1, Prdm14, Tcf3, Sall4, Esrrb, Tbx3, Stat3). Am Beispiel Trim24 cha-
rakterisierte ich genauere Gen-Loci der Co-Lokalisierung mit den OSN Faktoren.
Interessanterweise stellte sich in ChIP-seq Experimenten heraus, dass Trim24 mit
OSN auf vielen Super-Enhancern co-lokalisiert.
Im dritten Ansatz entwickelte ich eine Methode, um spezifisch Proteine zu iden-
tifizieren, die an einen bestimmten Promotor, in diesem Fall den Nanog-Promotor
gebunden sind. Die Spezifität der Methode, die biotinylierte Oligonukleotide ver-
wendet und Gezielte Isolierungsmethode genomischer Regionen (targeted isolati-
on of genomic regions, TIGR) genannt wird, wurde unter Verwendung von qP-
CR und Hochdurchsatz-Sequenzierung bestätigt. Mehrere Proteine, die bekannter-
maßen den Nanog-Promotor binden und dessen Transkriptionsaktivität regulieren,
wurden identifiziert. Vergleicht man den meta-stabilen mit dem Grundzustand der
Pluripotenz, identifizierte die TIGR Methode mehrere Nukleoporine (z.B. Nup98),
die an den Nanog Promotor bevorzugt im Grundzustand der Pluripotenz binden.
Dies konnte durch Verwendung von ChIP-PCR validiert werden.
Zusammenfassend erlauben die durch die oben erwähnten Methoden generier-
ten Datensätze ein erweitertes Verständnis der Regulation des Netzwerkes der Plu-
ripotenz. Zudem können die neu entwickelten Methoden stark verallgemeinert und
unabhängig von der Zellkultur oder Gentechnologie angewandt werden, und sind
daher für die Untersuchung ver- schiedenster biologischer Systeme relevant.
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1 Introduction andObjectives
A cellular phenotype is organized by the network of transcription fac-
tors (TF) dictating the cell-type specific gene expression profile. There-
fore, studying the TF networks and other chromatin-associated pro-
teins are necessary in order to understand how the cellular identity is
established. For example, during the development, TFs determine the
fate of the cells by inducing the expression of a set of genes required for
the differentiation pathway, and suppressing the alternative routes [1].
Additionally, in order to confine the cells in the correct track multiple
epigenetic modifications are added to DNA and chromatin by cytosine
methylation and histone marks, respectively [2, 3]. As a result, devel-
opment is unidirectional, and the differentiated cells are phenotypically
stable [4-6].
On the other hand, by applying different in-vitro or in-vivo treat-
ments [7] progressing in developmental processes is reversible. For
instance, by replacing the nucleus of an oocyte with that of a somatic
cell, it is possible to re-establish pluripotency [8-10]; the ability of a
cell to differentiate to all embryonic lineages. Moreover, fusing so-
matic cells with teratocarcinoma cells [11, 12], embryonic germ cells
(EGC) and ESCs [13] generates pluripotent-like cells. Finally evolving
these approaches has led to the induction of pluripotency in somatic
cells by expressing a few TFs [14]. The latter approach is the easiest
and the most viable way of producing patient-specific pluripotent stem
cells. Even by expressing a few TFs it is possible to change the cell
fate of somatic cells to another somatic cell type without pluripotent
intermediates [15-17]. As a result, these TF-based strategies for cellu-
lar reprogramming and trans-differentiation inspired many studies on
1
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the implicated mechanism in removing epigenetic properties in somatic
cells, and gaining the new TF networks. Unfortunately, TF-based re-
programming procedures in almost all cases are incomplete, inefficient
and time-consuming. Consequently, studying the involved mechanism
among heterogeneous population of the cells is very difficult. Here I
have summarized the current knowledge of reprogramming and cell-
fate engineering in chapter 2. In contrast to TF-based reprogramming,
induction of pluripotency by cell-fusion and nuclear transplantation is
rapid, as the pluripotency markers of the donor nucleus are detectable
within a few cell divisions [18, 19].Therefore, the question arises: what
factors in the pluripotent cells are able to erase the epigenetic memory
of the somatic cells. In other words, some chromatin-associated factors
in pluripotent cells are needed to assist the TFs to induce pluripotency.
Finding an answer for this question inspired me to focus on the dy-
namics of chromatin composition.
Nevertheless, studying chromatin composition is challenging due to
its complexity and the contaminants that may carry over during bio-
chemical purification of chromatin. Although chromatin is precipitated
easily by traditional centrifugation-based methods, many contaminants
may bind to chromatin during cell lysis and chromatin precipitation.
Additionally, there is no negative control for this approach, hence, it
is hard to rule out artifacts. Furthermore, the nuclear membrane and
the endoplasmic reticulum (ER) membrane are fused together. There-
fore, even if the nuclei are separated purely from the cytoplasm, it is
hard to distinguish between ER proteins and nuclear proteins. More-
over, nuclear proteins are not always bound to chromatin. In fact, it
is important to distinguish between the nucleosolic and the chromatin-
bound fraction of a given protein. Logically the latter one is more
relevant to gene expression regulations.
To distinguish contaminants from true chromatin-binding proteins,
Kustatscher et. al.[20] used a multi-classifier approach that assigns
a probability of chromatin-binding to each protein, called interphase
chromatin probability (ICP). Nevertheless, the fixed ICPs ignore the
fact that the chromatin composition is highly dynamic, and that many
2
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transcriptional regulators may bind to chromatin in a context depen-
dent manner.
Therefore, I sought to develop new enabling methods for reliable
isolation of chromatin-associated proteins using specific DNA-labeling
reactions by terminal deoxytransferase (TdT). Indeed, TdT is a template-
independent enzyme that adds biotinylated nucleotides specifically to
DNA. In addition, biotin-streptavidin is the strongest non-covalent in-
teraction, which allows very stringent washing steps. Taken together
these features provide a platform for developing a robust method for
selective isolation of chromatin-associated proteins (SICAP), which I
have developed and used for the first time to study the chromatin
protein composition (chromatome) in mouse ESCs in chapter 3.
I was also interested to look into the dynamics of chromatome
changes, therefore, two cellular states of pluripotency in mouse ES
cells were compared. Traditionally, mouse ES cells are cultured by
serum, which is referred to as the meta-stable state of pluripotency.
Alternatively, serum can be replaced by 2 protein kinase inhibitors
(2i)[21], PD0325901 and CHIR99021, driving the ES cells into a condi-
tion resembling the preimplantation epiblast, referred to as the ground
state of pluripotency [22]. In fact, PD0325901 inhibits mitogen acti-
vated protein kinase (Mek) to prevent Fgf4-mediated differentiation,
while, CHIR99021 improves cell viability and proliferation by inhibit-
ing glycogen synthase kinase-3 (Gsk3b) thus promoting Wnt signaling
[21]. As a result, 2i medium provides a better environment to maintain
pluripotency by eliminating fluctuations in the expression of pluripo-
tency transcription factors [23] like Nanog and Rex1 (Zfp42). Compar-
ing 2i and serum conditions provides an interesting model system for
studying epigenetic reprogramming as it has been shown that in serum
medium DNA is highly methylated, while, in 2i medium it becomes
demethylated [24].
Although SICAP is a robust tool for studying chromatome in a
global manner, protein composition of chromatin varies regionally ac-
cording to the different sites of the genome. Therefore, I was looking
for a more detailed approach to study the core transcriptional cir-
3
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cuitry of the pluripotency. To achieve this aim, I combined chromatin
immunoprecipitation (ChIP) and SICAP to identify chromatin-bound
interactants of the master TFs of pluripotency including Oct4, Sox2
and Nanog. As will be discussed in chapter 4, comparing 2i and serum
conditions using ChIP-SICAP reveals enhanced chromatin-binding of
several pluripotency-associated factors, while, their total quantity is
not regulated. This observation may give an answer to a question in
the field why the 2i condition is a better medium for the maintenance
of pluripotency. Furthermore, ChIP-SICAP validates SICAP results,
which I have used to verify Dazl chromatin-binding in chapter 4.
Although ChIP-SICAP reveals co-localization of proteins on the
genome, these do not necessarily occur in all genomic loci. Therefore,
I decided to develop a method for identification of proteins interact-
ing with any locus of interest. Although several researchers have tried
to achieve this aim by different approaches [25-27], none of them has
introduced a versatile method to the field. For targeted isolation of
genomic regions (TIGR), I designed specific oligonucleotide probes for
the Nanog promoter to identify the enriched proteins in comparison
the to the non-targeting probe. Using TIGR for comparing proteins
differentially associated with the Nanog promoter in the ground-state
and meta-stable state, it turned out that several nucleoporin prefer-
entially bind to the Nanog promoter in 2i medium. I validated this
result by ChIP-qPCR using Nup98 antibody, which will be explained
in chapter 5.
In chapter 6, I focused on somatic cell reprogramming to under-
stand the role of Nup210 in the induction of pluripotency. Finally, in
chapter 7 I discussed the advantages of the newly developed methods
in comparison with previous methods.
4
2 From Cell Fate Engineeringto Chromatin-AssociatedProteins
Cellular reprogramming essentially entails the removal of the epige-
netic memory of a somatic cell, and establishing a new transcriptional
network in order to achieve a new phenotype. The most extreme ex-
ample of reprogramming is the induction of pluripotency in somatic
mammalian cells by Oct4, Sox2, Klf4 and c-Myc [14]. After this ini-
tial discovery it was demonstrated that induction of pluripotency is
feasible by a combination of different TFs [28-31], miRNAs [32], and
even chemical compounds [33] (reviewed in [34]). Furthermore, it is
possible to change the identity of one cell type to another by express-
ing the master TFs of the target lineage, a procedure which is called
trans-differentiation [15-17]. Since the generation of induced pluripo-
tent stem cells (iPSC), it has received a lot of attention in field due to
its clinical potential. Therefore, during the last decade many groups
have been trying to elucidate the implicated mechanism of reprogram-
ming in order to improve it.
In principle, during the reprogramming procedure the epigenetic
properties of the somatic cells are gradually removed, being replaced
by a transcriptional circuitry that sustains pluripotency. Indeed, the
pluripotency transcriptional network is mainly regulated by the same
transcription factors that have been used to induce reprogramming.
In other words, the three master transcription factors Oct4, Sox2 and
Nanog not only are required for the maintenance of pluripotency in
the ES cells, but also are able to impose the pluripotency transcrip-
tional framework in the somatic cells. Therefore, studying chromatin
biology of pluripotency has been very helpful for understanding and
enhancing cellular reprogramming. Chromatin functions are carried
5
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out by numerous proteins. From histones and their modifications to
transcription factors and chromatin remodelers, many proteins are
involved in the maintenance of pluripotency. Despite genome-wide
RNAi-screening for the identification of regulators of pluripotency [35],
many regulators of pluripotency have remained uncharacterized due
to the inherent limitations of knock-down/out approaches (e.g. off-
target knock down, lethal consequence of knock down, insufficient
knock down, over-lapping functions of the proteins). On the other
hand, with the advancement of mass spectrometry in the recent years,
several proteomic approaches have emerged for identification of novel
chromatin-associated proteins. Thus in this chapter, I have reviewed
what we have learned so far from chromatin biology of pluripotency and
reprogramming. Then, I have covered the recent methods for studying
chromatin protein composition.
2.1 Chromatin-associated proteins involved
in cellular reprogramming
Upon expressing Oct4, Sox2, Klf4, Myc (hereafter as OSKM) the tran-
scriptional network of the somatic cells is perturbed, and gradually the
ES cells markers are expressed during a process that normally takes 2
weeks. Consequently, ES-like characteristics are established [36, 37].
It has been shown that OSK bind to various regions of the genome,
and have a pioneering role by recruiting other TFs and chromatin re-
modelers [38-40]. In fact, in order to reach to the pluripotent state,
somatic repressive heterochromatin should be converted to the ES-like
permissive euchromatin. Therefore, chromatin remodelers required for
the maintenance of the ES cells, such as esBAF (Brg-associated factors
in ES cells) [41] and Ino80 (inositol-requiring 80) [42], also play impor-
tant roles in reprogramming. As a result, expressing BAF or Ino80
components together with OSK facilitates binding of the TFs to their
targets, and improves the efficiency of reprogramming [42, 43]. On
the other hand, in the absence ofMbd3, a NuRD component required
for silencing pluripotency genes during differentiation of the ES cells
6
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[44], reprogramming is dramatically boosted [45], even without c-Myc
or Sox2 [46]. Nevertheless, this phenomenon seems to be a context-
dependent observation, as another study has claimed the necessity of
Mbd3 for reprogramming [47].
5mC
C
Compacted chromatin impermeable to reprogramming in somatic cells
Relatively permissive chromatin in the reprogrammed cells
esBAF
Ino80
TH2A
TH2B
Wdr5
Utx
Tet1/2
Lin28
Mbd3
macroH2A
Suv39H1/2
G9a
Jmjd3
Dnmt1
p53
Oct4 Sox2
Klf4
H3K9me3
H3K4me3
Figure 2.1: Chromatin-associated proteins influencing the somatic
cell reprogramming. In order to accomplish cellular reprogramming,
compact chromatin has to be opened, demethylated, and suppressive
histone marks such as H3K9me3 should be converted to H3K4me3.
Chromatin-associated proteins with positive and negative effect in
these procedures have been shown with green and red, respectively.
5mC: 5-methylcytosine. Adapted from [48].
In addition to the chromatin remodelers, histone variants also have
impact on the induction of pluripotency. Interestingly, TH2A and
TH2B, two histone variants highly present in oocytes, are able to im-
prove cellular reprogramming [49]. In fact, the expression of TH2A
and TH2B in somatic cells increases the DNase I sensitivity. There-
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fore, their contributions in reprogramming is probably mediated by
opening the chromatin structure [49].
In contrast to TH2A and TH2B, macroH2A is a barrier to repro-
gramming [50]. Interestingly, loss of macroH2A in ES cells interferes
with the differentiation of the cells due to the partial inactivation of
pluripotency genes during the differentiation [51].
Noteworthy chromatin-associated proteins related to the histone
modifications play important roles during cellular reprogramming. Wdr5,
a component of Trithorax complex, is required for efficient reprogram-
ming of somatic cells by rapid di-methylation of H3K4 in the initial
stage of reprogramming [52, 53]. Additionally, Wdr5 is involved in ES
cell self-renewal by regulating H3K4 methylation.
On the other hand, Suv39H1/H2 hinders reprogramming [39] by tri-
methylation of H3K9, which is a marker of heterochromatin regions.
In fact, OSKM do not bind to the genomic regions with this histone
marks. Therefore, knocking down Suv39H1/H2 enhances the efficiency
of reprogramming [39, 54]. Likewise, inhibiting G9a histone methyl-
transferase is beneficial for reprogramming due to the decreasing H3K9
di-methylation [55, 56].
Although decreasing H3K9 is helpful for reprogramming, the effect
of H3K27 tri-methylation on cellular reprogramming depends on the
enzymes and the loci. For instance, decreasing Utx, which is an en-
zyme with the ability to remove H3K27 tri-methylation [57], severely
affects reprogramming [58]. In fact, Utx removes H3K27 methylation
from the promoters of the pluripotency genes such as Fgf4, Sall4 and
Sall1.In contrast, down-regulation of Jmjd3, a H3K27 demethylase, im-
proves reprogramming by blocking Ink4/Arf expression and decreasing
cell senescence [59]. Additionally, for efficient cellular reprogramming
components of the PRC2 (polycomb repressive complex 2) are needed
to maintain H3K27 at least in some of their targets [54, 60].
One of the key events during the cellular reprogramming is demethy-
lation of the genome. In fact, DNA demethylation is critical for success-
ful iPS reprogramming, and reactivation of gene expression. Therefore,
aberrantly methylated promoters and enhancers may cause abnormali-
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ties in gene expression in the iPS cells, and incomplete conversions [61].
As a result, targeting Dnmt1 (DNA methyltransferse 1) by knock-down
or chemical compounds like Aza deoxy-Cytidine, significantly enhances
iPS cell generation [62]. Nevertheless, knocking down Dnmt3a and
Dnmt3b has almost no effect on reprogramming, suggesting that de
novo DNA methylation does not have a major role in dedifferentiation
[63].
Furthermore, Tet1 and Tet2 enzymes with the ability to oxidize
methyl Cytosine have been reported to contribute in somatic cellular
reprogramming [64, 65], as their knock downs affects the efficiency of
iPS cell generation. In the case of Tet1 this effect seems to be vita-
min C-dependent [66]. However, recently it has been shown that the
contribution of Tet1 and Tet2 is only until mesenchymal to epithelial
transition (MET), and knocking out all the Tet enzymes in epithelial
cells has no effect on reprogramming [67].
In addition to the TFs, and proteins related to the epigenetic prop-
erties, cell cycle regulators also impact iPSC generation. In fact, ES
cells have a relatively short cell cycle with a quick G1 phase, and
long S phase. Upon differentiation, the cell cycle is longer and the
G1 phase is dominated. Interestingly as an early event during cellular
reprogramming, the cell cycle changes, and becomes similar to that
of the ES cells [68]; as a result, the faster cell cycle the higher rate
of cellular reprogramming, and vice versa. Hence, down-regulation of
p53/p21 or over-expressing lin28 significantly accelerates the rate of
reprogramming [69]. It seems that replication of DNA provides a win-
dow of opportunity for OSKM or other TFs to bind to their targets
on the genome, before these regions are able to inherit the epigenetic
characters of the parental DNA [48].
Taken together, in all the aforementioned cases a chromatin-associated
protein with a critical role in the maintenance of the ES cells, con-
tributes to the somatic cell reprogramming. Thus by studying pluripo-
tency, and by applying new technologies for studying chromatin pro-
tein composition it should be possible to find potent candidates that
facilitate or accelerate iPS cell generation.
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2.2 Principles of the maintenance of pluripo-
tency in different states
Pluripotency is a potential capability of a cell in generating all cells
of an adult organism. Naturally pluripotent cells are generated during
embryonic day 4 (E4). At this time, the embryo is called blastocyst,
and consists of two cellular components: the inner-cell mass (ICM), and
the trophectoderm (TE). Before the implantation, the ICM cells are
also divided into two groups, the epiblast cells that homogeneously ex-
press Nanog, and the primitive endoderm cells that express Gata6 [70].
Developmentally the pre-implantation epiblast cells are at the ‘ground
state’ of pluripotency. In other words, these cells are the ancestors
of all future adult cells. Therefore, they are called ‘naive’ pluripotent
stem cells, which means they have no developmental bias [71]. Func-
tionally, these cells are able to produce a healthy and live embryo if
they are engrafted into a tetraploid embryo (4N complementation as-
say) [72]. In fact, the tetraploid cells are not capable of completing the
fetal development. At the later stage of the development (E5), when
the embryo has implanted, the epiblast cells are functionally called
‘primed’ pluripotent cells, as they are primed to start the differentia-
tion programs. As a result, these epiblast stem cells (EpiSC) are no
longer able to pass the 4N complementation assay [22].
From the epigenetic point of view, in the naive state the genome is
globally de-methylated, and the paternal X-chromosome is reactivated
in the female embryos. Therefore, epigenetically there is no boundary.
However, in the primed state the genome is methylated again, and the
cells are ready to start the lineage commitment programs [73]. Interest-
ingly by applying appropriate in vitro conditions it is possible to pause
the cells in the pluripotent stage. Initially this was achieved by cultur-
ing ICM cells using serum-containing medium on a layer of the inacti-
vated fibroblast cells, which is called the feeder layer. Later it turned
out that the feeder layer secretes a factor (leukemia inhibitory factor,
LIF) that supports the self-renewal of the ES cells [74, 75]. Therefore,
the feeder cells can be omitted if LIF is added to the medium, and a
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supportive extracellular matrix like gelatin applied to the culture plate
for attaching the ES cells to the plastic. The ES cells grown using
serum and LIF with or without feeder are called ‘serum’ ES cells.
Indeed, LIF supports self-renewal of the ES cells, by the activa-
tion of JAK kinase and the Stat3 pathway. Without Stat3, adding
LIF to the medium does not contribute to the self-renewal of the ES
cells. Conversely, overexpression of Stat3 is enough to keep the ES
cells undifferentiated without adding LIF [76]. It seems that Stat3 in-
duces the expression of Tfcp2l1, which is also a TF. In fact, Tfcp2l1
is necessary for LIF-responsiveness, and its forced expression supports
LIF-independent self-renewal [77, 78].
It has been shown that Bmp4 is the critical component of serum,
as in the absence of serum it allows the maintenance of the ES self-
renewal together with LIF [79]. In fact, Bmp4activates the expression
of Inhibitor of differentiation (Id) genes via the Smad pathway [79].
Culturing the ES cells using serum and LIF supports the naive
pluripotency, as the ES cells are able to contribute to the chimeric
mouse, or tetraploid embryos. However due to the undefined composi-
tion of serum, contradicting signaling pathways are activated in the ES
cells. As a result, there is quite some heterogeneity among the serum
ES cells, as pluripotency markers such as Nanog and Rex1 fluctuate
between high and low level of expression [80-82].In other words, some
cells have kept their naive pluripotent identity, and some others are
primed to differentiate. Nevertheless, these subpopulations of the ES
cells dynamically convert their identity [83]. Therefore, the serum ES
cells are considered to be in a ‘metastable’ state of pluripotency [73].
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Figure 2.2: Diversity of pluripotent stem cells. Functionally ICM-
derived stem cells are called naive pluripotent stem cells. Culturing
the ICM-derived cells in 2i medium, with or without LIF, stabilizes
naive pluripotency. ES cells cultured in 2i medium are closely similar
to the ICM cells (the ground state). Although, serum and LIF stabi-
lizes naive pluripotency, the ES cells are heterogeneous from different
aspects (the meta-stable state). Following implantation of the em-
bryo, stem cells derived form epiblast (EpiSCs) are functionally called
primed pluripotent stem cells, as they are primed to be differentiated.
Furthermore, primordial germ cells (PGCs) can generate embryonic
germ cells (EGCs) by in vitro culturing, which are highly comparable
to the ES cells. Adapted from [73]
CHAPTER 2. FROM CELL FATE ENGINEERING TO CHROMATIN-ASSOCIATED PROTEINS
After years of studying on the signaling pathways in the mouse ES
cells, it turned out that FGF/ERK pathway is responsible for triggering
differentiation of the ES cells. Therefore, by adding a specific chemical
inhibitor of the FGF pathway (PD0325901, or PD03) to the medium of
the ES cells, they are able to self-renew without LIF or serum [21]. In
order to improve the viability and self-renew of the cells, the chemical
inhibitor of GSK3 (CHIRON) was supplemented, as well [21, 84, 85].
Therefore, the new serum-free medium is called ‘2i’ referring to the 2
chemical inhibitors.
While PD03 prevents differentiation of the ES cells, inhibition of
Gsk3 by CHIRON stabilizes B-Catenin. As a result, B-Catenin moves
into the nucleus, and prevents the repressive effect of Tcf3 on Oct4 and
Sox2 [86]. In fact, Tcf3 depletion prevents differentiation of the ES cells
[87], and substitutes Gsk3 inhibition [88] for improving self-renewal.
Remarkably, the 2i ES cells homogeneously express the pluripotency
markers such as Nanog and Prdm14. In addition, the genome of the
ES cells is globally de-methylated [89, 90]. Furthermore, 2i ES cells
contribute to the chimera embryos with a higher rate in comparison to
serum ES cells. Importantly, using 2i medium germ line-competent ES
cells can be generated from impermeable strains like non-obese diabetic
(NOD) or FVB [91-93]. Therefore, the ES cell grown in 2i medium
satisfy the definition of naive pluripotency better than the serum ES
cells, nevertheless, both of them are functionally considered as naive
pluripotent stem cells. However, in terms of transcriptional signature
and epigenetic profile, the serum ES cells are different with the pre-
implantation epiblast cells, while, the 2i (with or without LIF) ES cells
are closely similar to the ground-state epiblast cells. In fact, single-cell
transcriptome analysis indicates that 2i ES cells are clustered closely
with E4.5 epiblast cells [94, 95]. Therefore, serum ES cells are not
characterized as ground-state, whereas, the 2i (+LIF) ES cells are the
most similar representative of the ground-state epiblast cells in in-vitro
conditions [73].
As was mentioned previously, the identity of the ES cells primarily
depends on three master transcription factors, Oct4, Sox2 and Nanog
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(OSN), which together constitute the core-transcriptional circuitry of
pluripotency. Additionally, they recruit other pluripotency auxiliary
TFs such as Tbx3, Esrrb, Klf4, Klf2, Sall4, Stat3, Tfcp2l1 and Prdm14
etc. to specific enhancers and promoters in order to maintain the tran-
scriptional network of pluripotency [73]. Although the auxiliary TFs
are markers of pluripotent stem cells, depending on 2i or serum con-
ditions they may become essential or dispensable for the maintenance
of pluripotency. For instance, in serum condition Stat3 and Tfcp2l1
are indispensable [77], while, Esrrb and Klf2 are not required for the
maintenance of pluripotency. Conversely, in 2i medium the latter two
TFs are indeed essential [96], whereas, Stat3 and Tfcp2l1 are not im-
perative. Although 2i medium is a better condition for persevering
pluripotency, OSN and most of the pluripotency auxiliary TFs do not
dramatically change in expression level between 2i and serum condi-
tions at least at the level of mRNA. For example, Oct4, Sox2, Nanog,
Tbx3, Esrrb, Klf4 and Klf2 do not show significant changes, while,
Prdm14, Dppa3 (Stella), Tfcp2l1 and Tcl1 are up-regulated 3-fold
[95]. On the other hand, Utf1, Lin28b and Id genes are down-regulated
in 2i medium (between 2 to 5-fold). Therefore, one remaining ques-
tion in the field is how 2i medium provides a better tuned condition
for the ES cells, while there is no such a significant change in the ex-
pression of pluripotency-associated genes [97]. Furthermore, Myc is
dramatically down-regulated in 2i medium ( 32-fold). In fact, such
an intensive down-regulation of Myc may bring about cell cycle ar-
rest, which is not tolerated in the ES cells, and may lead to their
differentiation. Thus another unanswered question is how 2i ES cells
are able to compensate the loss of the Myc network. One of the re-
markable differences between 2i and serum conditions, is the reduction
of global DNA methylation in the 2i ES cells [24, 89, 98]. Basically,
ICM cells are globally hypomethylated just before the implantation [99,
100], whereas, after the implantation the genome of the epiblast cells is
methylated again. Interestingly, the hypomethylation occurs rapidly in
2i medium, and it can be acquired on the correct genomic sites in the
serum medium [6]. Initially it was thought that TET-mediated oxida-
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tion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) is
needed for the demethylation of DNA. However, Tet1 and Tet2 knock
out ES cells are still able to demethylate their genome in 2i medium.
Surprisingly, knocking out Prdm14 in the ES cells prevents their DNA
hypomethylation in the 2i condition [90, 101]. It seems that Prdm14
contributes in DNA demethylation by suppressing the expression of de
novo DNMTs [90], and by promoting the activity of the TET enzymes
[102].
In contrast to male ES cells, the genome of the female ES cells
is hypomethylated in serum condition. It has been shown that the
hypomethylation of the female genome is due to the activation of both
X chromosomes. As a result, MAPK and Gsk3 pathways are inhibited,
and Akt pathway is stimulated [103].
In addition to DNA methylation, histone marks are different be-
tween 2i and serum conditions. For example, H3K27me3, a histone
mark generated by PRC2, is depleted in the 2i condition [104]. This
could be due to the inhibition of ERK pathway, as it is required for
the activity of Eed [104]. Interestingly, PRC2 is not required for the
maintenance of pluripotency, however, it is needed for appropriate dif-
ferentiation of the ES cells. Therefore, removing H3K27me3 mark from
developmental genes does not activate them, indicating that there are
other mechanisms for repressing the differentiation genes in the ES cell
[95]. In 2i condition RNA polymerase 2 (Pol II) is paused at the proxi-
mal promoters more frequently than the serum condition especially at
the promoter of developmental genes. Thus PolII pausing could be an
important transcriptional regulatory mechanism in the ground state of
pluripotency.
Recent studies claim that H3K9me2 and H3K9me3, the histone
marks of heterochromatic regions, are globally lower in the 2i condi-
tion [89]. On the other hand, H3K4me3, an activating histone mark,
increases in 2i medium. At the same time, Padi4 is up-regulated, which
is able to convert arginine to citrulline on histone H1. As a result, chro-
matin is decondensed [105].
In contrast to the 2i and serum conditions for preserving naive
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pluripotency, primed pluripotency is stable by adding bFgf and Activin
A to the medium of the EpiSCs [106]. EpiS cells are able to differentiate
in-vitro, and to generate teratoma in-vivo, however, they are not able
to contribute in chimeric mouse. In comparison to the ES cells, EpiSCs
express Esrrb, Klf4, Klf5, Nanog, Prdm14 and Zfp42 (Rex1) at lower
levels [107]. In addition, the female X-chromosome is deactivated in
the EpiS cells, and the promoters of pluripotency-associated genes are
methylated. Furthermore, pluripotent stem cells can be derived from
primordial germ cells (PGC). Hence, they are called embryonic germ
cells (EGC), which are almost indistinguishable from the ES cells [89].
Altogether, plasticity of pluripotent stem cells in transforming from
one state to the other state of pluripotency provides valuable model sys-
tems for studying cellular reprogramming. Indeed, chromatin-associated
proteins are at the core of maintaining and abolishing pluripotency.
Hence by developing new enabling tools for studying chromatin biol-
ogy we should be able to tackle the unanswered questions, gain new
insight in the mechanism of gain and loss of pluripotency, and design
new approaches for improving somatic cell reprogramming.
2.3 Novel methods for studying chromatin-
associated proteins
In order to understand the functions of the genome, it is essential to
study the organization of proteins that occupy the genome and that
regulate its function. Therefore, in the Encyclopedia of DNA Elements
(ENCODE) project, many research groups have contributed to pro-
file the binding sites of TFs and other chromatin-associated proteins
on the genome. In addition to the TF-occupancies, characterization
of histone modifications and their localizations on the genome were
the other goals of the ENCODE. To achieve these goals, Chromatin
immuno-precipitation (ChIP) coupled to the high-throughput sequenc-
ing (ChIP-seq) has been the method of choice. Furthermore, to shed
light on the 3D structure of the genome they have studied long-range
DNA-DNA interactions by methods such as Hi-C and ChIA-PET.
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Although ChIP-seq has been a very successful method, by definition
it targets proteins one at a time and thus does not uncover the protein
composition of chromatin in an unbiased manner. Indeed, due to the
artifacts associated with the isolation of chromatin, identification of
novel chromatin-associated proteins by mass spectrometry has been
challenging. Nevertheless, recently in parallel with advances in mass
spectrometry, several new methods have been developed to reveal the
complex array of chromatin-associated proteins. Here I have described
some of these novel methods developed since 2009, to discuss their
advantages and limitations.
One of the problems in adapting the ChIP method for proteomics
studies is the large amount of the background proteins. In fact, ChIP-
seq takes the advantage of DNA sequencing as the read-out, which
provides two dimensions for the signal: 1- location of the signal on
the genome, and 2- the intensity of the signal. As result, the differ-
ences with the negative control is determined easily when the intensity
of the signal is mapped throughout the genomic loci. However, using
mass spectrometry only the intensity of the signal can be used as the
read-out. In other words, the enriched proteins are identified using a
ratio in comparison to the negative control. Using the gentle washing
steps that are applied to the ChIP procedure, it is hard to remove the
background proteins efficiently, which is sufficient when targeting only
a single protein as in ChIP, but which becomes problematic when us-
ing an unbiased approach such as mass spectrometry. Therefore, some
true positives are rejected because of lack of sufficient enrichment, and
on the other hand some false positives are included among the true
positives due to the inadequate removal of the background proteins.
To solve this issue, two methods have been developed, modified ChIP
(mChIP) [108] and ChIP-MS (mass spectrometry)[109], both of which
somehow used tandem affinity purification (TAP)-tagging for increas-
ing the signal to noise ratio.
In mChIP, no formaldehyde cross-linking is used. Instead, chro-
matin is fragmented by sonication, or using micrococcal nuclease (MNase)
digestion, followed by tandem-affinity-purification (TAP) tagging. Then
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proteins are resolved using the SDS-PAGE to remove the antibody
bands from the other proteins, and finally the proteins are digested to
be injected to the mass spectrometer for protein identification. Indeed,
TAP-tagging makes the IP very specific, and makes the method feasi-
ble for the proteins without proper antibodies. However, the efficiency
of IP is quite low, and when it is carried out two times sequentially
it becomes even less efficient. As a result, a massive number of input
cells is needed (10 billion cells), which is normally only achievable for
yeast cell culture but not mammalian cells.
In ChIP-MS, however, robust formaldehyde cross-linking is applied
(3%, 30 min). In addition, the target protein has a His-tag, and a
bacterial peptide sequence to be biotinylated using the endogenous
biotin-ligases (HTB-tag). Therefore, no antibody is needed, and the
target protein can be captured using streptavidin beads. As a result,
stringent washing can be applied to remove the background proteins.
This method was used for the first time to study the dosage compen-
sation in drosophila using 1 billion cells as the input. Although the
amount of required cells is less than the previous method, still it is not
routinely achievable. In addition, using mChIP or ChIP-MS tagging
the proteins may affect the function of the bait, or may bring about
artifacts due the expression level of the bait.
In line with the aforementioned methods, chromatin proteomics
(ChroP) [110] is a method for identification of chromatin-associated
proteins using histone modifications as the bait. There is no need to
tag the bait histones, probably because histones are very abundant,
which may help to improve the signal to noise ratio. Additionally,
ChroP has been applied to mammalian cells using 100 million cells.
The above mentioned methods focus on a target protein to identify
physical interactions in a global fashion. To identify proteins associ-
ated with the locus of interest, Dejardin and Kingstone have developed
a method called proteomics of isolated chromatin fragments (PICh)
[111]. In this method they have used a biotinylated oligonucleotide
as the probe to target the telomeres in human and drosophila cells.
Additionally, they have successfully targeted pericentromeric regions
18
CHAPTER 2. FROM CELL FATE ENGINEERING TO CHROMATIN-ASSOCIATED PROTEINS
in mouse ES cells [112]. The main advantage of this method is that
it is independent of antibodies. In fact, designing and synthesizing an
oligonucleotide probe is much simpler than producing a ChIP-grade
antibody. However, so far it has only been useful for the target loci
with tens of copies per genome.
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Figure 2.3: The recent methods for studying chromatin can be di-
vided into two groups: Protein-targeted methods (including mChIP,
ChIP-MS and ChroP), and Loci-targeted methods (PICh and ChAP-
MS). A) In mChIP the target protein is purified by TAP-tagging. B) In
ChIP-MS the target protein is expressed in conjunction with a bacterial
peptide to be biotinylated by endogenous biotin-ligases. C) In ChroP,
histone modifications are targeted by specific antibodies, to identify the
co-localized proteins. D) In PICh the target loci are captured using a
biotinylated oligonucleotide probe. E) in ChAP-MS LexA-binding site
is engineered in the target locus, and subsequently it is captured by
expression and immuno-precipitation of LexA. T1: Tag1, T2: Tag2.
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Another method to identify proteins that bind to a given genomic
locus is called chromatin affinity purification with mass spectrometry
(ChAP-MS)[25]. In this method, LexA-binding site is integrated adja-
cent to the locus of interest. Then LexA is expressed in the cells to bind
to the engineered locus. Using this method, proteins-associated with
Gal1 locus have been studied in yeast in the presence of Glucose and
Galactose to turn the target locus transcriptionally off and on, respec-
tively. Although some of the expected proteins have been identified
using this method, the amount of required input cells is enormously
high (100 billion cells). In addition, cloning the LexA- binding site is a
barrier for expanding this method to other cellular systems, and may
interfere with the expression of the target loci. To circumvent this, in-
stead of LexA-binding site transcription activator-like (TAL) was used
for targeting the locus of interest [26]. However, it seems that TAL does
not bind to the Gal1 locus when the expression is turned off. In other
words, TAL binds to the transcriptionally active targets. Altogether,
identification of chromatin-associated proteins certainly contributes to
understanding the mechanism of transcriptional regulation, but is tech-
nically challenging. Therefore, many investigator shave attempted to
develop novel methods for achieving this aim. It is clear that there are
some gaps in the methods to be filled to circumvent the shortcomings
of current methods. For example, mChIP, ChIP-MS and ChroP fail to
answer a question: are the identified proteins located on the chromatin,
or are they soluble interactants of the bait proteins? Beyond multi-copy
loci such as telomeres, are we able to identify proteins that associate
with a single locus? Answering these questions demands developing
new methods, which will be discussed in the following chapters.
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Chromatin is an organized cellular complex that contains genomic
DNA together with proteins and RNAs [113], which are required for the
repair, duplication and transcription of the genome. A wide array of
proteins is involved in each of these biological processes, and therefore
the identification of the implicated proteins is absolutely essential to
gain better mechanistic insights into genome regulation. Constructing
the global view of chromatin has remained challenging due to the back-
ground proteins associated with chromatin purification. Chromatin is
a very large complex with the propensity to precipitate easily after cell
lysis. In addition, DNA is a highly charged molecule; therefore, many
non-specific chromatin proteins may bind to chromatin during cell ly-
sis. The traditional method developed for the purification of chromatin
[114] does not have a proper negative control to rule out the contami-
nants. For instance, mitotic chromosomes, which are quite dense and
distinguishable, could be isolated using sucrose and Percoll gradients
[115]. Although this approach was used to identify new substrates of
Aurora B Kinase [116], there are many non-canonical proteins. Con-
sidering that there is no negative control for density centrifugation, the
final list of proteins may look unreliable. To solve this problem recently
Ohta et. al. [20] have used machine learning approaches with different
classifiers called multiclassifier combinatorial proteomics (MCCP) to
set up a random forest analysis. As a result, chromosomal proteins
were distinguished with high specificity. Nevertheless, the classifiers
used in this study are feasible for mitotic chromosomes. Consequently,
the method can not be extended to interphase chromatin. Many im-
portant transcription factors and chromatin remodelers detach from
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the condensed chromosome during mitosis. Therefore, more recently
Kustatscher et. al. [20] used a similar bioinformatic approach to de-
fine interphase chromatin probability (ICP) for proteins. Although this
approach could be useful in specific cases [117], it does not reflect the
dynamic essence of chromatin binding due to the fixed probabilities
that are assigned to the proteins. In other words, for some transcrip-
tion factors such as STATs or SMADs always low ICPs are considered,
while depending on the model system of interest these factors may bind
more or less to chromatin.
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Figure 3.1: Schematic presentation of SICAP. For further details,
please refer to the text (section 3.1).
In this study to avoid the problems of traditional chromatin-prep
methods with the background proteins, and to take the dynamics of
chromatome into consideration practically, I developed a new method
called Selective Isolation of Chromatin Associated Proteins (SICAP,
fig. 3.1). Using SICAP we are able to specifically label DNA, and
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purify the in-vivo fixed chromatin fragments from many other protein-
complexes.
3.1 Designing a new approach for captur-
ing chromatin
To identify the global protein composition of chromatin in an unbiased
way, I developed SICAP. To do that, first of all I treated mouse ES cells
with formaldehyde 1.5% (v/v) for 15min to cross-link proteins to DNA
essentially like in the established ChIP protocols [118]. To exclude
proteins cross-linked via RNA, I added RNase A to the samples. Next
I treated the sample with terminal deoxynucleotidyltransferase (TdT)
in the presence of biotin-ddUTP in order to specifically label free 3’-
ends of DNA. Chromatin fragments were captured using streptavidin
beads. Then the beads were washed extensively by SDS 1%, NaCl 2M,
iso-propanol 20% (v/v) and Acetonitrile 50% (v/v) in water. Finally, to
break the crosslinks the samples were boiled (fig. 3.1). As the negative
control, essentially the same procedure was carried out just without
adding biotin-ddUTP, hence, chromatin fragments were not labeled.
Finally, the proteins were loaded on SDS-PAGE to be compared with
the negative control. As a result, it turned out that SICAP enriches
for proteins with very low background from non-specific binding of the
proteins to the beads (fig. 3.2A). This was further investigated by
quantitative mass spectrometry to identify proteins enriched relative
to the negative control using SICAP.
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Figure 3.2: Comparing SICAP with the negative control. A) SDS-
PAGE shows the proteins enriched by SICAP procedure with and with-
out biotin-ddUTP. B) The efficiency of recovering DNA for three in-
dependent replicates relative to the input was calculated using qPCR.
C) The fluorescent microscopy of the cells using streptavidin-Alexa488
indicates. In the first row: using TdT and biotin-ddUTP the nuclei
are labeled; but neither cytoplasm nor nucleoli. In the second row:as a
negative control, biotin-nucleotides were not added to the cells. In the
third row: using Poly-U polymerase and biotin-UTP in addition to the
nuclei, cytoplasm and nucleoli are stained. The white arrows indicate
nucleoli, which shows a strong signal using RNA-labeling.
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3.2 Evaluating the specificity and efficiency
of chromatin purification by SICAP
Although TdT adds nucleotide specifically to DNA (not RNA), to be
more confident about the specificity and efficiency of DNA-labeling I
utilized a microscopy assay. Briefly the cells were fixed, and then they
were treated with DNase I to produce nicks in DNA. Subsequently the
cells were treated with TdT and biotin-ddUTP. Then the cells were
exposed to Streptavidin Alexa-fluor 488.
Fluorescent microscopy clearly demonstrated efficient and specific
staining of nuclei, but not cytoplasm nor nucleoli (fig. 3.2C, top row).
Conversely to see the difference of RNA-labeling with DNA-labeling,
I replaced TdT with Ecoli polyU polymerase; in addition, I replaced
biotin-ddUTP with biotin-UTP. As a result, this time I observed cyto-
plasmic signal, and the intensive staining of nucleoli (fig. 3.2C, bottom
row). Although in this experiment I used DNase I to produce nicks
in DNA, in SICAP I omitted this step to avoid biases due to DNase I
hypersensitive sites. In SICAP, chromatin is chopped into small frag-
ments by sonication, hence, chromatin fragments are labeled by TdT.
Therefore, there is no need to make nicks by DNase I. In addition, I
checked the efficiency of DNA recovery, which has turned out to be
about 3-5% relative to the input DNA fig. 3.2B. Thus using SICAP
the in-vivo fixed DNA-protein complexes are efficiently and specifically
enriched such that only with 4 million cells I identified many chromatin
proteins; while, the most recent study has used 100 million cells [20]
for chromatin enrichment for proteomics (ChEP).
3.3 Identification of chromatin composi-
tion in mouse embryonic stem cells
Although I loaded the SICAP samples on SDS-PAGE to visually com-
pare it with the negative control (fig. 3.2A), proteins purified by SICAP
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are free of detergents. Therefore, after tryptic digestion and desalting,
the peptides can be injected to the mass spectrometer. In order to
decrease the complexity of the sample, I divided the peptides into 10
fractions using high pH reverse phase liquid chromatography (pH =
10). As a result, after protein digestion and mass spectrometric analy-
sis 5231 proteins were identified using two independent replicates, 5106
of which were significantly (adj. p-value ≤ 0.05) enriched over the neg-
ative control (fig. 3.3A and Supplementary Table 3.1) as determined
by a moderated t-test using the limma package [119]. Once again this
result confirms very low non-specific background proteins by SICAP.
To assess whether prior evidence may link these 5106 proteins to
chromatin, I referred to Gene Ontology (GO) as well as the presence
of DNA or chromatin binding domains. The GO database provides
evidence for nuclear localization of 2794 proteins (fig. 3.3B) while 806
proteins have been annotated as chromatin or DNA-binders. These
include many transcription factors known to be involved in stem cell
maintenance such as Oct4, Sox2, Nanog, Klf4, Tcf3, Vps72, Stat3,
Esrrb, Sall4, Lin28, Rbpj, Tbx3, Notch1, B-Catenin and Nkap.
Moreover 1407 proteins are involved in biological processes related
to chromatin functionality, including transcriptional regulators such
as RNA polymerase II subunits as well as many components of the
mediator complex. Some plasma membrane proteins would not be
expected to be present in this group (i.e. Arf4, Atp2b4, Lims1, Rab23
etc. fig. 3.4A and Supplementary Table 3.1). Interestingly some of
these membrane-proteins (i.e. E-cadherin [120], Dab2ip [121], Mavs
[122], Rab23 [123] and Tlr2 [124]) have been shown to be involved in
nuclear import and might thus interact with chromatin in the process.
Additionally, I found 1574 proteins with DNA or chromatin binding
domains, most of which have indeed been annotated with GO-terms
related to nuclear localization or as DNA or chromatin-binder proteins,
with the exception of 334 proteins (fig. 3.4B). Gene enrichment analy-
sis of these 334 proteins indicated that 25 proteins are involved in trans-
lation (i.e. proteins with canonical aminoacyl-tRNA ligase activity or
translation initiation factor activity). Interestingly, aminoacyl-tRNA
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synthetases have been reported in the nuclei as a high molecular weight
complex [125]. Furthermore 28 proteins are involved in protein trans-
port with DNA/chromatin-binding domains (i.e. proteins involved in
vesicle-mediated transport proteins such as Sec23a, Sec23b, Sec24a,
Sec24c, Sec24d, Sec31a with zinc finger domains).
Figure 3.3: Identification of the enriched proteins by SICAP. A) Sig-
nificantly enriched proteins by SICAP (adj. p-value ≤ 0.05) and the
background proteins were stained by green and gray dots, respectively.
The yellow dot shows nuclear localization based on CC of GO. Histones
have been shown by an additional red rectangle B) the enriched pro-
teins were categorized based on CC = Nucleus (Yellow), MF = DNA or
Chromatin binding (Red), BP = Transcriptional-regulation, DNA re-
pair, DNA replication and chromatin modification (Chromatin-related
processes, Blue), DNA or chromatin binding domain (Purple) and HPA
sub-cellular localization = Nucleus (Orange). C) the relative intensi-
ties of the proteins have been shown for each of the aforementioned
categories.
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Figure 3.4: Unexpected proteins enriched by SICAP. A) The Venn di-
agram shows proteins annotated by GO as transcriptional-regulation,
most of which have nuclear localization, except some plasma mem-
brane proteins. B) The Venn diagram shows proteins with DNA or
chromatin binding domains, most of whichhave nuclear localization or
they are in fact chromatin-binders. Some proteins involved in transla-
tion or protein-localization do not have nuclear localization based on
GO. C) The Venn diagram shows proteins with nuclear signal based
on HPA database, most of which overlap with GO. However, based on
HPA some proteins involved in translation or protein-localization have
nuclear localization.
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In order to check the localization of these proteins I consulted the
Human Protein Atlas (HPA [126]). Mapping all 5106 SICAP-enriched
proteins to HPA revealed nuclear localization for at least 2400 pro-
teins in our list, among which 650 proteins that had not been anno-
tated as a nuclear protein based on GO database (fig. 3.4C). Inter-
estingly, this included Sec23a, Sec24b and Copa (involved in vesicular-
trafficking), Cars2, Ears2, Lars2 (amino-acyl tRNA synthetases) and
Eif2b2, Eif2b4, Eif4h (translation initiation factors) thus supporting
our SICAP data. It should be noted that protein annotation based on
staining in the human cancer cell lines used in HPA may not be taken
as a direct proof for nuclear localization in the mouse ES cells used in
our study. Conversely, absence of such localization in HPA does not
disprove our SICAP results.
Importantly, by considering the relative intensities of the enriched
proteins about 75% of them are localized in the nucleus, while, 17% of
the enriched proteins have no known relevance to the chromatin (fig.
3.3C). To more directly correlate SICAP-derived chromatin-interaction
to nuclear localization in mouse ES cells I selected 132 proteins from
our SICAP data without prior GO annotations related to nuclear local-
ization or functionality. Immuno-fluorescence microscopy using HPA-
validated antibodies revealed nuclear localization of 62 proteins (fig.
3.5, and Supplementary Table 3.2) including proteins involved in vesic-
ular trafficking (i.e. Sec14L1, Rab8a, Ankfy1), as well as translation
(i.e. Rpl8).
It is noteworthy that detecting nuclear localization by immuno-
fluorescent and chromatin-binding by SICAP are not equivalant; but
complementary evidence. In fact, a nuclear protein may or may not
bind to chromatin. For example, p53 is a nuclear protein, however,
it binds to DNA only once it is activated. On the other hand, using
immuno-fluorescent microscopy we may see a strong plasma membrane
signal for E-cadherin. Nevertheless, it does not disprove the chromatin
binding of the protein [127].
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Figure 3.5: Immuno-fluorescent staining of some proteins enriched by
SICAP with previously unknown nuclear localization using HPA anti-
bodies. Blue shows nuclei (DAPI staining), Red shows microtubules,
and green shows the target proteins. 62 out of 134 proteins clearly show
nuclear localization. Fro further details, please refer to the Supplemen-
tary Table 3.2. These immuno-staining experiments were carried out
by Dr. Peter Thul, KTH Royal institute of Technology.
Altogether, SICAP has indicated that chromatin composition is
much more diverse than previously expected. Thanks to the high speci-
ficity of TdT in labeling DNA, the ability to eliminate contaminating
proteins by extensive washing, and comparing with a non-biotinylated
negative control, SICAP is a reliable approach.
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3.4 Comparing chromatin protein compo-
sition between the ground-state and
the metastable state of pluripotency
To achieve a new cellular state, chromatin should recruit some proteins
in order to regulate the expression of a specific set of genes. To identify
the recruited/dismissed chromatin proteins in a high-throughput man-
ner I used SICAP to quantitatively compare the chromatin composition
of ES cells in the ground-state (2i conditions) and the meta-stable state
of pluripotency (serum conditions) after labeling cells with heavy and
light SILAC amino acids, respectively. In addition, I obtained full pro-
teome data from the same cells to investigate the correlation between
changes in protein levels and chromatin localization. The SICAP and
total proteome experiments identified 5232 and 6461 proteins, respec-
tively, each quantified with a Pearson correlation of 0.85 between
biological replicates indicating high reproducibility (fig. 3.6A, B and
Supplementary Table 3.3). Qualitative comparison of SICAP and pro-
teome datasets indicate that 357 proteins were only identified using
SICAP (fig. 3.6C) such as Nanog and Klf4 (fig. 3.6A, B). This may
be readily explained by the higher complexity of the full proteome and
the enrichment of otherwise low abundance chromatin-bound factors
via SICAP, rendering them accessible for mass spectrometric detection.
These proteins mainly represent processes related to transcription (fig.
3.6C) as may be expected for a chromatin-enriched pool of proteins.
Comparing the chromatome of the two cell states using SICAP in-
dicates about 1518 and 1521 proteins differentially associate with chro-
matin in 2i and serum media, respectively (adj. p≤0.05, fig. 3.6A).
Comparing the full proteomes of the two cellular conditions reveals
about 1500 differentially expressed proteins in each of the media (adj.
p≤0.05, fig. 3.6B); however, GO analysis of proteins higher in 2i
medium indicated that the SICAP data is more enriched for chromatin-
related biological processes in comparison to the full proteome and the
transcriptome data by Marks et. al. [95] (fig. 3.7A, and Supplementary
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Table 3.3).
Figure 3.6: Comparing 2i and serum condition of the ES cells by
SICAP and full proteome. A and B) proteins significantly higher in
2i and serum were stained in red and blue, respectively (p-value ≤
0.05). Proteins without significant change were stained in gray. C)
The Venn diagram shows proteins identified only by SICAP and the full
proteome, which are significantly enriched in transcriptional-regulation
and proteolysis, respectively. P: p-value of the enrichments, R: Pearson
Regression
In addition, SICAP data were enriched in processes related to
(m)RNA processing, suggesting the capture of proteins involved in
co-transcriptional regulation at chromatin. In serum medium the most
significant enriched genes using SICAP are involved in non-coding RNA
metabolism and translation (fig. 3.7B, and supplementary table 3.3).
In fact, rRNA transcription and maturation occur co-transcriptionally
in the nucleolus [128]; in addition, tRNA aminoacylation [125] and
translation [129, 130] have been reported in the nucleus. Given the
fact that translation-related genes are not up-regulated according to
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the full proteome comparison, their differential binding to chromatin
in serum condition suggests other non-canonical functions that remain
to be determined.
When directly comparing full proteome to SICAP data, changes
in protein expression levels between 2i and serum conditions showed a
reasonably high correlation with differences in chromatin association
(R=0.58, fig. 3.8A). For instance, Dnmt3a and Dnmt3b were among
the strongest enriched proteins in serum condition in both data sets,
suggesting global DNA methylation in the meta-stable state. Addi-
tionally, only SICAP data indicate that Uhrf1, required for the main-
tenance of 5mC significantly binds to chromatin in serum condition.
This is in line with bisulfite sequencing results by Habibi et. al [24] and
with the current model of decreased DNA methylation and enhanced
transcription in 2i cells.
Among the proteins with the strongest increase in chromatin-binding
and overall expression in 2i cells we observed an uncharacterized pro-
tein Gm13128/Pramef17. Interestingly Gm13128/Pramef17 is highly
similar (70% identical) to Pramel7, which has been identified for its im-
portant role in the maintenance of pluripotency in the ES cells acting
downstream of LIF-Stat3 signaling [131]. PRAME was first identi-
fied as an antigen expressed in human melanomas [132]. Interestingly
members of PRAME family, which contain Leucine-rich repeats, are ex-
pressed preferentially in gametogenic tissues and in tumors [133]. Our
observation that Pramef17 is highly expressed and binds to chromatin
in 2i medium may indicate an unknown chromatin-related function of
the PRAME family in pluripotency, as well.
Surprisingly we observed Fgf4 among the prominent up-regulated
chromatin binders in the ground-state of pluripotency (fig. 3.8A). This
is highly unexpected since Fgf4 is a growth factor not known to asso-
ciate with chromatin. Interestingly, immuno-fluorescent staining using
a monoclonal antibody indeed confirmed strong nuclear localization of
Fgf4 in addition to staining in the plasma membrane as expected for a
secretory protein (fig. 3.8B).
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Figure 3.7: Enrichment analysis of the biological processes for the
significant genes in A) 2i medium, and B) serum medium using SICAP
(green), full proteome (orange) and transcriptome (yellow, data pro-
duced by Marks et. al. [95])
To further investigate whether ES cells possess a mechanism to
transport Fgf4 to the nucleus we generated a stable HEK cell line
expressing HA-tagged Fgf4. Treating ES cells with the filtered condi-
tioned medium followed by immuno-fluorescent staining using an HA-
antibody revealed nuclear localization of Fgf4 mainly in cells outside
the ES cell colony, again with additional staining in the plasma mem-
brane (fig. 3.8C). This indicates that secreted Fgf4 is able to move
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into the nucleus in a paracrine fashion. Interestingly, Fgf4 is known to
induce differentiation by a pathway that is inhibited by the combined
effects of the Mek2 and Gsk3b (i.e. 2i) inhibitors. It remains to be
determined if nuclear localization provides a mechanism to silence the
differentiation-promoting function of Fgf4.
Although changes in chromatin interaction in 2i versus serum con-
ditions closely follow overall expression for most proteins, about 235
proteins showed a significant difference in chromatin binding without
an appreciable change in their total abundance (fig. 3.8A). Such a
pattern indicates dynamic association with chromatin controlled by
other mechanisms than translational regulation. For instance, the tran-
scriptional regulators Oct1 and Pbx2 show an 8 to 16-fold increase in
chromatin-binding in 2i condition, without a change in their total quan-
tity (Supplementary Table 3.3). Another interesting example is Scml2,
a polycomb repressive complex 1 (PRC1) associated protein, that binds
to chromatin globally in 2i condition. It seems that Scml2-binding to
chromatin occurs independently of PRC1 and PRC2, since the other
members of these complexes do not show significant changes in ex-
pression or chromatin binding. In serum conditions, the transcription
factor Casz1 and histone acetyltransferase Kat2A are highly enriched
in chromatin. The fact that these prominent examples all concern
bona fide chromatin components with established roles in transcrip-
tional regulation suggest that they may fulfill important functions in
sustaining ground or meta-stable states of pluripotency. Shuttling to
chromatin independent of altering their expression level may provide
a mechanism to do so in a fast manner.
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Figure 3.8: Quantitative comparison between the SICAP and the full
proteome dynamics. A) The plot shows full proteome and SICAP ratios
between 2i to serum on the x and y-axis, respectively. There are 235
proteins without significant change in their total quantity while their
chromatin-binding is significant. B) Immuno-staining by monoclonal
antibody (MAB) against Fgf4 indicates nuclear localization of Fgf4 in
the ESCs. C) Fgf4 fused with the HA-tag was added to the medium of
the ES cells, and then immuno-staining was carried out using anti-HA
antibody. As a result, nuclear localization of the tagged protein was
observed. The white arrow indicates the ligand probably in the cell
membrane.
4 ChIP-SICAP: RegionalView of Chromatin
Chromatin immuno-precipitation (ChIP, [134, 135]) is a powerful method
for finding the genome-wide identification of binding sites of a given
transcription factor. At the end of this procedure, the enriched DNA
fragments are identified by qPCR, microarray chips [136], or high-
throughput sequencing [137]. Therefore, the antibody, contaminant
proteins or non-chromatin-bound proteins do not interfere with the
final read-out, as they are removed during the procedure of DNA pu-
rification. However, injecting the ChIP samples into the mass spec-
trometer usually does not produce reliable results due to contaminat-
ing proteins. In fact, many non-specific proteins such as cytoplasmic
proteins may stick to the beads, the plastic tubes or even DNA. Using
gentle washing steps applied to the ChIP procedure it is hard to remove
the contaminant proteins, and as a result the final sample is not clean
enough to demonstrate reproducible and reliable results. In addition,
the target protein of the ChIP is not always attached to the chromatin,
hence, it may carry over many non-chromatin-bound interactants.
Hence I developed a solution for double purification and exclud-
ing the non-chromatin-bound proteins by combining ChIP and SICAP
(ChIP-SICAP, fig. 4.1). Using this method, I studied proteins in the
vicinity of Oct4, Sox2 and Nanog (hereafter OSN) on chromatin in or-
der to identify novel proteins connected to the core-circuitry of mouse
ESCs in 2i and serum media. In other words, using ChIP-SICAP we
can study proteins on small fragments of DNA with the target protein,
which I call co-localized proteins on chromatin. It is noteworthy that
co-localized proteins (identified by ChIP-SICAP) do not necessarily in-
teract directly with the bait protein, but they are in close vicinity to
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the bait protein on the same DNA fragment (in average about 200-bp).
Therefore, it is conceivable that they have functional cross talk.
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Figure 4.1: Schematic representation of ChIP-SICAP. For further
details, please refer to the text (section 4.1).
Here I identified 408 proteins, as the result of OSN ChIP-SICAP. These
408 proteins include a large number of established interaction partners
of the target proteins known to participate in the core pluripotency
network (e.g. Rex1, Prdm14, Tcf3, Sall4, Esrrb, Tbx3, Stat3 etc).
Interestingly, it turned out that many of these regulators of pluripo-
tency do not show such a significant change in their total quantity,
however, their chromatin bindings are significantly different in 2i and
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serum media. In addition, I identified many proteins as novel compo-
nents of the core-circuitry. Therefore, I selected Trim24, as a protein
remained undetected by the previous affinity capture methods, to ver-
ify the ChIP-SICAP result. Interestingly it turned out that Trim24
binds to OSN on many critical genomic loci such as Nanog, Prdm14,
Tbx3 and Sox2 enhancers preferentially in 2i medium.
Then I focused on Suz12 and the co-localized proteins on chromatin.
In fact, polycomb group (PcG) proteins have important roles during
development. Specifically, polycomb repressive group 2 (PRC2), which
Suz12 is a member of, represses transcription via di- and trimethylation
of lysine K27 on histone H3 (H3K27me2/3). As a result of applying
Suz12 ChIP-SICAP, the entire PRC2 plus many known interactors of
Suz12 were identified.
4.1 Experimental design and proof-of-principle
I first carried out ChIP-SICAP using a Nanog antibody in ES cells
cultured with heavy-SILAC 2i medium compared to a negative con-
trol cultured with light-SILAC 2i medium. In the negative control I
excluded the Nanog antibody, however, I included the DNA biotinyla-
tion step. As a result, 640 proteins were identified, out of which 557
proteins were significantly higher in the Nanog antibody-treated sam-
ple over the negative control (adj. p-value ≤ 0.05, fig. 4.2A, B and
Supplementary Table 4.1).
Ranking the identified proteins based on their estimated intensities
indicates that histones are the most abundant proteins, followed by
Nanog and its (potential) interaction partners (fig. 4.2C). This obser-
vation alone leads to two important conclusions, namely i) that the
antibody has pulled-down the expected target, thereby independently
validating the antibody, and ii) that Nanog co-purifies all nucleosome
histones proving that it binds to chromatin. This is in contrast to
previous Nanog affinity-capture assays (BioGrid), which were unable
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Figure 4.2: Nanog ChIP-SICAP in comparison to the no-antibody
control. A) The scatterplot shows proteins non-significant and signif-
icantly enriched proteins (adj. p-value ≤ 0.05) over the no-antibody
control by gray and green color, respectively. B) The Venn diagram
shows the overlap of the two replicates. C) The plot shows the esti-
mated intensities of the significant proteins and their ranking from top
to down.
to identify the histones. In fact, using co-immunoprecipitation chro-
matin is sedimented to avoid its binding to the beads, and then soluble
interactants are pulled down.
Of the 557 identified proteins, 112 overlapped with the 270 proteins
previously identified to interact with Nanog (as deposited in BioGrid)
(fig. 4.3A). Comparing the outersects of the datasets (442 and 158
proteins from ChIP-SICAP and the previous affinity captures, respec-
tively) indicates that Regulation of transcription is the most significant
biological process (BP) that has been identified in both protein groups
(fig. 4.3B). Nevertheless, using ChIP-SICAP the number of proteins
associated with the BP term is higher, and the p-value of the enrich-
ment is also less. The relatively small intersect ( 20%) indicates that
the scope of chromatin-associated proteins identified by ChIP-SICAP is
quite different to that of the soluble interactants found by other meth-
ods. In fact, without DNA-labeling it is hard to distinguish between
these two sets of networks.
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Figure 4.3: Comparing ChIP-SICAP with the previous affinity pu-
rification methods for Nanog. A) The Venn diagram shows the overlap
of Nanog ChIP-SICAP (green) with the previous affinity purification
methods (yellow, reference: BioGrid). B) Comparing the enriched bi-
ological processes between the outersects. NE = not enriched, PV =
p-value of the enrichment.
4.2 Comparing Oct4, Sox2 and Nanog co-
localized proteins on chromatin be-
tween 2i and serum media
Being confident of detecting only a few background proteins in the no-
antibody control, I next compared proteins co-localized with Nanog,
Oct4 and Sox2 using ESCs grown in serum (light medium) and 2i
medium (heavy SILAC). In these experiments heavy and light cells
were combined from the beginning of the assay, therefore chromatin
fragments of both samples were simultaneously labeled by biotin-ddUTP.
Firstly, I performed ChIP-SICAP using Nanog. I detected 650 pro-
teins, out of which about 300 proteins were significantly different be-
tween 2i and FBS conditions (adj. p-value≤ 0.1, fig. 4.4A, and Supple-
mentary Table 4.2). Interestingly using Nanog ChIP-SICAP, B-catenin
has the highest fold-change of chromatin-binding in 2i compared to
serum condition (>20-fold difference). This is expected from the fact
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that one of the kinase inhibitors in 2i medium is Gsk3b inhibitor
(CHIR99021), resulting in activation of Wnt signaling and transloca-
tion of B-catenin to the nucleus co-localizing with Nanog on chromatin.
We also detected Oct4 and Sox2 in association with Nanog binding
sites, which is consistent with the tight interconnection of the three
factors in the proposed model for the core transcriptional circuitry of
the ES cells [138]. Additionally, we observed several factors related to
stem cell maintenance that differentially associate with Nanog bind-
ing sites in 2i medium, including Prdm14, Tfcp2l1, Rex1(Zfp42), Tcf3
(Tcf7l1), Sall4, Esrrb, Tbx3, Stat3, Klf4, Tfap2c, Smarca4 (Brg1) (Fig-
ure 4.4A). Indeed, prior studies have shown the important roles of these
proteins in either stem maintenance or reprogramming to pluripotent
stem cells.
Remarkably, in serum condition we observed all nucleosome com-
ponents including histones H2A, H2B, H3, H4 and multiple histone H1
variants with significantly higher ratios compared to 2i. Therefore, it
seems that DNA is more accessible to Nanog in 2i medium, while DNA
is relatively more packed around Nanog-binding sites in serum condi-
tion. This indicates that ChIP-SICAP can inform on global chromatin
structure. Finally, Nanog preferentially interacts with DNAmethylases
(Dnmt3a, Dnmt3l, Uhrf1) under serum conditions. Extending these
experiments to Oct4 and Sox2 as entry-points for differential ChIP-
SICAP between 2i and serum conditions essentially reproduced the
results for Nanog, with subtle differences (fig. 4.4B, C). Importantly,
each experiment identified all three master TFs, confirming the close
connection between OSN in the pluripotency network. Like Nanog,
ChIP-SICAP using Oct4 and Sox2 also shows a high ratio of B-Catenin
in 2i medium, although with a less extreme ratio for Sox2. Interest-
ingly most of the nucleosome components did not show a significant
change using Oct4 and Sox2 ChIP-SICAP, however, macroH2A1 and
macroH2A2 are surprisingly higher for Oct4 in 2i condition. Indeed,
macroH2As are transcriptionally-suppressive variants of H2A [139-141]
therefore, it seems that in 2i condition some of the Oct4 targets are
repressed by recruiting macroH2A.
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Figure 4.4: Comparative ChIP-SICAP between 2i and serum con-
ditions using Nanog, Oct4 and Sox2 as the target (bait). Proteins
significantly higher in 2i, serum and non- significant proteins are red,
blue and gray, respectively (adj. p-value ≤ 0.1).
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Figure 4.5: Proteins co-localized with Oct4, Sox2 and Nanog on
chromatin. A) The Venn diagram shows the overlap of Oct4, Sox2 and
Nanog ChIP-SICAP. B) Categorization of the 408 proteins based on
GO terms and protein domains.
4.3 Studying the core-transcriptional cir-
cuitry of mouse embryonic stem cells
Here I reasoned that proteins identified repeatedly using Oct4, Sox2
and Nanog ChIP-SICAP are most likely connected to the core-circuitry.
Therefore, after subtracting the potential false-positives identified in
a no-antibody ChIP-SICAP in ES cells in 2i and serum media (pri-
marily endogenously biotinylated proteins such as pyruvate carboxy-
lase, Mccc1, Mccc2 and so on), I identified 408 proteins in the overlap
among the three ChIP-SICAP experiments (fig. 4.5A). This represents
the large majority of the proteins in the individual experiments (77%
of Oct4, 44% of Sox2 and 62% of Nanog 70-80%) indicating the tight
interaction within the network. GO annotation of these 408 proteins
indicate that 86% (351 proteins) have a nuclear localization while 49%
(200 proteins) have a DNA-binding or chromatin-binding function, in-
dicating the enrichment of proteins with the expected functionality.
Furthermore, about 10% of the proteins (43 proteins) have no annota-
tion relating them to nucleus, DNA-binding, chromatin-binding or the
relevant domains (fig. 4.5B).
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Figure 4.6: Ranking the proteins based on their estimated intensities.
Each ChIP-SICAP experiment indicates the target protein on top of
the intensities, after the histones. Using Cdh1(E-Cadherin) neither
Oct4, Sox2, Nanog nor many other proteins were identified, and vice
versa.
Because of the very high overlap between the OSN ChIP-SICAP
experiments we aimed to verify that results were not accidental by
carrying out a ChIP-SICAP experiment using E-Cadherin (Cdh1) as
a protein foreign to the pluripotency network. In fact, E-cadherin is a
plasma membrane protein rather than a canonical chromatin-binder,
however, it can be cleaved by gamma-secretase, gamma-secretase and
caspase-3 releasing specific C-terminal fragments (E-Cad/CTFs) 1, 2
and 3, respectively, which are able to translocate into the nucleus and
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bind to chromatin [142]. As expected, ranking of identified proteins
in the Cdh1 ChIP-SICAP assay indicated that Cdh1 is one of the
most intense proteins after the histones (fig. 4.6). Interestingly, Cdh1
was identified mostly by C-terminal peptides. In addition, its known
interactors Beta-Catenin and Delta-Catenin (p120) were identified, of
which the latter is required for nuclear localization and DNA-binding
of (E-cad/CTF2) [142]. While p120 and several other proteins were
specifically identified using Cdh1, neither Oct4, Sox2, Nanog nor many
other stem cell maintenance factors were detected in the Cdh1 ChIP-
SICAP experiment. Thus protein-DNA interactions revealed by ChIP-
SICAP are specific, and depend on the protein used as a bait.
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Figure 4.7: The heatmap of the overlapping proteins based on their
2i/Serum ratios by ChIP-SICAP. Cdh1 (E-Cadherin) is clustered dif-
ferently with Nanog, Oct4 and Sox2. The first vertical cluster was
enlarged in the right panel. The green genes are known components of
the core-circuitry of pluripotency.
Specificity was further confirmed by clustering of the OSN and
Cdh1 ChIP-SICAP results, where Oct4, Sox2 and then Nanog clus-
tered together while Cdh1 was separated as an out-group (fig. 4.7).
In addition, many stem cell regulators tightly grouped together, in-
cluding Nanog, beta-catenin, Rex1, Tcf3, Tbx3, Kdm3a (Jmjd1a) and
Prdm14 Remarkably, Prdm14 is one the most prominent factors whose
association with the OSN network is strongly induced in 2i conditions.
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In fact, Yamaji et al [143] have previously shown that Prdm14 has an
important role in the generation of primordial germ cells (PGC) by epi-
genetic reprogramming and re-establishing pluripotency. Furthermore,
we found that several components of the BAF complex (Smarcd2,
Smarcb1, Smarcc1, Smarcd1 and Smarca4) as well as histone demethy-
lases Kdm3a (Jmjd1a) and Kdm3b (Jmjd1b) are significantly higher
in 2i medium (all adj. p-value ≤ 0.1, fig. 4.8). This is in line with their
demonstrated role in promoting reprogramming or regulating pluripo-
tency (e.g. Smarcc1 (BAF155) and Smarca4 [144]; Smarcd1 (Baf60a,
[145]), Kdm3b and Kdm3a [146, 147]).
4.4 Verification of Trim24 as a novel com-
ponent of the core-circuitry
Among the novel candidates in the first cluster in fig. 4.7, I observed
Trim24, an E3-ubiquitin ligase that subjects p53 to degradation [148].
Since Trim24 has not been associated with the pluripotency network
before, we decided to verify the co-localization of Trim24 with OSN
by ChIP-seq. Interestingly the ChIP-seq result revealed that Trim24
co-localized with OSN in about 800 enhancers (fig. 4.9A, B), includ-
ing 70 super-enhancers defined by Whyte et. al. [149]. Additionally,
Trim24 preferentially binds to 443 enhancers in 2i-condition compared
to serum medium, which is in line with our proteomic data. Interest-
ingly these enhancers are close to genes involved in negative regulation
of cell differentiation (fig. 4.9C, D i.e. Nanog, Lif, Nr0b1 and Gli2,
gene enrichment p-value 3.08E-5, Supplementary Table 4.3). Addi-
tionally, based on the genome-wide occupancy of p53 in mouse ES
cells [150] and our ChIP-seq data, Trim24 and p53 co-localize on sev-
eral of the ESC super-enhancers (fig. 4.9E), remarkably including the
super-enhancers of Nanog, Prdm14, Sox2 and Tbx3. Thus it is con-
ceivable that the effect of p53, a potent inhibitor of pluripotency, on
these super-enhancers is moderated by Trim24 in 2i medium, possibly
by its targeting for degradation. Alton et al have shown that knocking
down Trim24 in mouse ESCs leads to p53-dependept apoptosis [148].
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Figure 4.8: Prominent proteins identified by OSN ChIP-SICAP. The
first three bars indicate the 2i over serum ratios obtained by Oct4, Sox2
and Nanog ChIP-SICAP, respectively. The forth bar indicates the full
proteomic comparison of 2i and serum.
Figure 4.9: The co-localization of Oct4, Sox2, Nanog and Trim24
on the ES enhancers A) The Trim24 ChIP-seq profile of the signals on
the non-super-enhancers of the mouse ESCs. The non-super-enhancers
have been defined by Whyte et. al. [149] B) The ChIP-seq profile of the
signals on super-enhancers defined by of the mouse ESCs. The super-
enhancers have been defined by Whyte et. al. [149]C) The enriched
biological processes associated with the genes around the up-bound
enhancers in 2i condition. D) The profile of the ChIP-seq signal on
Nanog super-enhancers. E) The Venn diagram shows where Trim24
and Trp53 are co-localized on the super-enhancers. The Trp53 binding
sites were obtained from [150].
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4.5 Studying proteins co-localized with PRC2
on chromatin
After applying ChIP-SICAP to the core-transcriptional regulatory cir-
cuitry of the mouse ES cells, I used this method to study proteins
co-localized with Suz12, and hence PRC2 proteins in these cells. In
mammalian cells PRC2consists of 6 core components: Suz12, Ezh2 or
Ezh1, Eed, Rbbp4 and Rbbp7, which are involved in silencing gene
transcription. Remarkably, PRC2 proteins have important roles in ex-
pressing developmental genes; such that by knocking out Suz12, Ezh2
or Eed mouse embryos die on day E7.5 to E8.5 [151-153]. Identification
of proteins co-localized with PRC2 proteins on chromatin may help us
to understand how they are recruited to the target genes to be silenced.
To achieve this goal, I carried out Suz12 ChIP-SICAP in the wild
type ES cells, and as the negative control I used Suz12 knock-out
(SKO) ES cells. Additionally, I reversed the SILAC labeling between
the replicates as an independent biological replicate. In other words, in
the first replicate the wild type ES cells are labeled with heavy SILAC,
and the SKO ES cells are labeled with light SILAC; and vice versa in
the second replicate. Hence I mixed the wild type and the SKO ES
cells from the beginning of the assay thereby minimizing experimental
bias. As a result, 383 proteins were identified as the intersect of two
replicates (fig. 4.10A, B and Supplementary Table 4.4), out of which
348 proteins were significantly enriched compared to the negative con-
trol (adj. p-value ≤ 0.1). A few background proteins were identified
using both replicates in the knock out samples. In fact, in this case
knock out control is the best negative control, and evaluates the off-
target binding of the antibody. This indicates the benefit of double
purification by the target protein and by DNA.
As expected I observed all 6 core components of PRC2. Further-
more, ranking the identified proteins based on the estimated intensities
shows histones and Suz12 and the other PcG proteins as the most abun-
dant proteins. Interestingly I observed two isoforms of Mtf2, which are
required for binding of PRC2 to the repressed Hox genes, and the inac-
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tive X-chromosome [154, 155], as well as the global level of H3K27me3
in mouse ES cells [156]. In fact, the first 102 aminoacids of the isoform
1 are missing in the isoform 2, consequently the Tudor domain is lost.
It has been shown that the Tudor domain binds to methylated H3K36,
and it is required for the recruitment of PRC2 by Mtf2 [156]. However,
it is not yet known what the function of the isoform 2 is.
Figure 4.10: Suz12 ChIP-SICAP: A) The scatterplot indicates the
enriched proteins by targeting Suz12 in comparison to the Suz12 knock-
out control with red and gray dot, respectively (adj. p-value<0.1). B)
The proteins were ranked based on their estimated intensities. C)
qPCR demonstrates enrichment of Suz12 targets Olig2 and Fgfr3 in
comparison to the background Chrm1 and ActB. The DNA was re-
trieved from a ChIP-SICAP sample prep.
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Moreover, I observed Jarid2 co-localized with Suz12. Indeed, it has
been demonstrated that Jarid2 binds to many PcG target genes. In
addition, it is essential and sufficient for recruiting PcG proteins, as
well as differentiation of the ES cells and proper development [157].
Furthermore, using Suz12 ChIP-SICAP I identified several uncharac-
terized proteins such as AU022751 and Gm340, which are interesting
candidates to determine their functional relevance with PcG proteins.
All combined, these results demonstrate the power of ChIP-SICAP
identifying all known core and peripheral PRC2 proteins in a single ex-
periment with high confidence, in addition to several new candidates.
Additionally, I wanted to retrieve DNA at the end of the ChIP-SICAP
procedure. Therefore, one can carry out qPCR, sequencing and mass
spectrometry in parallel with one sample prep. To achieve this aim, I
used SP3 peptide purification after the protein digestion [158]. In fact,
using this protocol the peptides bind to paramagnetic beads coated
with carboxyl groups by acetonitril as an organic solvent. I assumed
that DNA fragments do not bind to the beads, and therefore I kept
the acetonitril supernatant. Then I evaporated the liquid, and I re-
constituted the solution by Tris-HCl 10mM. After that I subjected
the solution to phenol-chloroform-isoamylalcohol procedure to purify
DNA. Finally, qPCR results demonstrated a successful enrichment of
Suz12 binding sites such as Fgfr3 and Olig2 in comparison to ActB and
Chrm1 (fig. 4.10C). Thus, using ChIP-SICAP, not only the protein co-
localizations are detected, but also DNA can be retrieved to be used
for qPCR or sequencing.
4.6 ChIP-SICAP is the reciprocal valida-
tion of SICAP
In chapter 3 using the SICAP procedure I have shown that many known
chromatin-binding proteins together with the novel ones are identified
making use of the fact that SICAP captures DNA, followed by iden-
tification of DNA-interacting proteins by mass spectrometry. As a
reciprocal validation for the novel chromatin-binding proteins one may
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utilize ChIP-SICAP, in which a protein is immuno-precipitated and
then DNA is labeled to isolate the chromatin-bound proteins from the
other interactants. In particular, ChIP-SICAP will provide stronger
evidence of chromatin-binding compared to immuno-fluorescence mi-
croscopy, which at best can show nuclear localization, while adding the
advantage of directly validating the specificity of the used antibody.
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Figure 4.11: Proof of chromatin-binding for Dazl by ChIP SICAP.
A) Sorting the identified proteins by ChIP-SICAP based on their in-
tensities indicates histones on top following Dazl. B) Proteins with
log2 average >0 were considered as true positives, as Dazl is highly
up-regulated in 2i medium. Looking at the GO terms associated with
the enriched protins indicates several proteins with DNA/RNA-binding
functions.
Here I selected Dazl from the SICAP data as a non-canonical chro-
matin bound protein, yet showing a strongly induced association to
chromatin in 2i condition (Supplementary Table 3.3). Dazl is a cyto-
plasmic mRNA-binding protein that binds to the 3’-UTRs [159] and
inhibits the translation of key transcripts during the development of
primordial germ cells including Sox2, Rex1(Zfp42) and Sall4, as well
as pro-apoptotic genes such as Caspase 7 [160]. In addition, Dazl
enhances translation of Tet1 resulting in a global increase in DNA-
hydroxymethylation in mouse ES cells grown in 2i conditions [161].
Dazl was identified in SICAP despite the treatment of the samples
with RNase A and the use of TdT which specifically reacts with DNA
but not RNA, thus lending strong support to the notion that Dazl is
a genuine DNA-interacting protein. In addition, another 900 RNA-
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binding proteins were uncovered, suggesting that proteins interacting
with both DNA and RNA may be a common phenomenon. To directly
show that Dazl associates with chromatin and to identify its inter-
action partners we used an antibody against Dazl in a ChIP-SICAP
approach comparing ES cells in 2i and serum conditions following dif-
ferential SILAC labeling. Of note, Dazl is much higher expressed in 2i
cells (Supplementary Table 3.3), thus we expected to see that the true
co-localizers would higher in 2i medium.
Interestingly we identified histones as the most abundant proteins,
then Dazl, and then several other proteins that are capable of bind-
ing to RNA and DNA such as Pum2, Fus, HNRNPs, Sfpq, Ddx3x,
Srrt, Tardbp, most of which are higher in 2i medium (Figure 4.11 and
Supplementary Table 4.5). As a result, we can confirm the chromatin-
association of Dazl, which may indicate Dazl binding to its targets
during transcription.
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Although ChIP-seq is a powerful method, it determines the binding
sites for one protein of interest in each experiment. If we would like to
identify all the proteins that associate with a given locus, it is hard to
carry out ChIP-seq for hundreds of proteins. The traditional method
for this aim is an in-vitro assay, in which short oligonucleotides en-
compassing the given sequence are immobilized on beads, and then
treated with the nuclear lysate [162-164]. Finally, the enriched pro-
teins in comparison to the negative control are identified by mass spec-
trometry or western blotting. Using this method normally hundreds of
proteins are enriched in comparison to the negative controls, which is a
clear indication of non-specific proteins bound to short oligonucleotides
( 45-bp)[165]. In addition, depending on how stringently the samples
are washed, the final result might be different and non-reproducible.
Therefore, the best solution is capturing the in-vivo fixed chromatin
to avoid such artifacts. To achieve this aim Dejardin et al. have de-
veloped a method called proteomics of isolated chromatin fragments
(PICh)[166]. In PICh after cross-linking using formaldehyde, chro-
matin is fragmented by sonication and then the loci of interest are iso-
lated using biotinylated oligonucleotide probes. Specifically, he used
locked nucleic acid (LNA)-based probes to enhance the hybridization
of the probe with the target, which is cross-linked to the proteins.
Using this method Dejardin could detect the proteins associated with
the telomeres and pericentromeric regions [166-168] benefiting from the
fact that each has tens of copies per cell. Unfortunately, they stated
in his article [166] that PICh is not sensitive enough to detect single
locus-associated proteins. Here I tried to improve this strategy by a
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self-invented protocol for targeted isolation of genomic regions (TIGR).
In fact, by changing the probe-hybridization conditions TIGR method
is more convenient and efficient. In this study I applied TIGR to the
Nanog promoter, and then I confirmed the specificity of the targeting
by high-throughput sequencing. Following injecting the sample into
the mass spec about 800 proteins were reproducibly identified, among
which there are tens of known Nanog promoter binding proteins. Fi-
nally using ChIP-qPCR, I validated Nup98 as a novel protein that
binds to the Nanog promoter.
5.1 Experimental design of the assay
To lyse the cells, and partially purify chromatin I used DNAzol. DNA-
zol is a mixture of guanidinium and other denaturing reagents for ex-
traction of genomic DNA. In the original protocol of DNAzol, ethanol is
used to precipitate DNA. However, I found out that cross-linked chro-
matin precipitates just by spinning at 5000g without adding ethanol.
Therefore, by removing ethanol less contaminant proteins precipitate
together with the chromatin. Furthermore, in order to improve the effi-
ciency of hybridization I used NaOH, which is used in Southern blotting
for DNA denaturation and probe hybridization. After the sonication
to fragment chromatin into shorter pieces, I added the oligonucleotide
probes. Then I changed the buffer to bring the pH back to the neu-
tral condition. As a result, DNA is renatured, and the probe may
bind to its target. Moreover, heating at 55 ◦ C to 65 ◦ C for 5 min is
also necessary to hybridize the probe efficiently. Since formaldehyde
cross-linking is sensitive to heating, I did not heat above 65 ◦ C for 5
min, while, in PICh protocol essentially hybridization is carried out by
heating to 71 ◦ C for 7 min, and without adding NaOH.
In this study I designed two adjacent probes for the Nanog promoter
and one non-targeting probe. The probes work efficiently when the
lengths are 50 bp. In fact, comparing the ratios of the Nanog probe to
the scramble probe provides a means to rule out background proteins.
Additionally, comparing the result of the two adjacent probes indicates
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the reproducibility of the results.
In order to check the enrichment of the Nanog promoter, I carried
out qPCR for the Nanog promoter and a few other genomic loci includ-
ing Slc2a3, which is the nearest gene to the Nanog locus. Furthermore,
the isolate DNA fragments were subjected to next-generation sequenc-
ing. Then I injected the proteins obtained by the protocol to the mass
spectrometer (fig. 5.1).
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Figure 5.1: Schematic presentation of TIGR procedure. For more
information, please refer to the text (section 5.1).
5.2 Evaluating the specificity and efficiency
of TIGR
To check the specificity of targeting, the isolated chromatin fragments
were subjected to DNA extraction and qPCR. It turned out that Nanog
promoter is enriched 9000 to 10000-fold in comparison to the scram-
bled controls (fig. 5.2A). Additionally, the efficiency of recovering the
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target was calculated by comparing with an input control, which is
not subjected to pull down. The result indicated that between 17% to
19% of the chromatin fragments encompassing the Nanog promoter are
recovered (fig. 5.2B). Moreover, the enrichment was calculated by com-
paring with the scramble probe. Furthermore, the pulled down samples
were ligated to the Illumina linkers and submitted to high-throughput
sequencing. As a result, it turned out that the Nanog promoter is the
major peak, which encompasses a region <1 kb around the binding
sites of the probes (fig. 5.2C). and the non-specific peaks are much
less intense and non-reproducible. Altogether, TIGR efficiently and
specifically targets the locus of interest.
5.3 Identification of proteins associated with
the Nanog promoter
After confirming the specificity of the TIGR pull down, the samples
were prepared for injecting to the mass spec. In this assay, the two
Nanog specific probes Nanog-519 and Nanog-453, positioned just 10
bp apart in the Nanog-locus, were applied to the cells already grown
with heavy and intermediate SILAC labels, respectively. In addition,
the scramble probe was applied to the light-SILAC cells. After hy-
bridizing the probes, the three samples were mixed and subjected to
streptavidin pull down. Following stringent washing steps and revers-
ing the cross-linking, the samples were injected at once into the mass
spectrometer. The ratios of the proteins identified by Nanog specific
probes over the scramble probe were calculated, and significantly en-
riched proteins were determined. Interestingly the proteins identified
by the independent probes are very well correlated, and their over-
lap is very high (fig. 5.3A, B and Supplementary Table 5.1). There
are 841 proteins at the overlap of the two Nanog probes, which make
sense for a 1kb fragment of the chromatin. Looking at the biological
processes enriched among these 841 proteins, ‘regulation of transcrip-
tion’ is significantly enriched (fig. 5.3C). Additionally, many Nanog
binding proteins were identified such as Oct4, Smarca4, p53, Sall4 and
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B-Catenin (fig. 5.3D). Moreover, some general transcription factors
and pol2 members were identified among the enriched proteins. Taken
together, the enriched proteins are relevant to the target locus, there-
fore, it is worthwhile validating the unknown interactants.
Nanog-519 Rep1
Nanog-519 Rep2
Nanog-453 Rep1
Nanog-453 Rep2
Chromosome 6
A)
C)
B)
Nanog-519 Rep1
Nanog-519 Rep2
Nanog-453 Rep1
Nanog-453 Rep2
Figure 5.2: TIGR efficiently and specifically enriches the Nanog pro-
moter. A) The bar chart indicates the enrichment of the Nanog pro-
moter, and the most intense off-target binding sites. The enrichment
was calculated over the scramble (non-targeting) control. The locations
of the off-target sites were determined by high throughput sequencing.
B) The percentage of recovering the Nanog promoter relative to the
input control. C) The tracks indicate the enrichment of the sequenc-
ing reads throughout the chromosome 6. Nanog-519 and Nanog-435:
probes targeting the Nanog promoter at 519 and 453bp upstream of
translation start site, respectively.
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5.4 Comparing the Nanog promoter-associated
proteins in 2i and serum conditions
In order to find the proteins related to the regulation of the Nanog
promoter among the novel candidates identified in the previous ex-
periment, I compared the two conditions of pluripotency by culturing
the ES cells in 2i+LIF (2iL) and serum conditions. In fact, in 2iL
medium Nanog has a more homogenous expression pattern among the
cells. Therefore, comparing 2iL and serum condition is an interesting
model system for finding Nanog promoter regulators. Thus I applied
a Nanog probe using the established TIGR protocol, to the ES cells
grown in 2i and serum media with heavy and light SILAC labeling,
respectively. In this experiment the identified proteins were quanti-
tatively compared between 2iL and serum (fig. 5.4A, Supplementary
Table 5.2). In order to remove the non-specific proteins I looked at
the overlap of this experiment with the previous one (fig. 5.4B). Once
again many known interactors of the Nanog promoter were identified,
most of which do not show such a significant change between 2i and
serum in term of binding to the Nanog promoter, except Lamin A.
Looking into the potentially novel proteins that differentially bind to
the Nanog promoter, many of them are nuclear proteins and some of
them are cytoplasmic (fig. 5.4C). Therefore, this experiment provided
additional information about the dynamics of the proteins recruited
to the promoter. Although several known Nanog promoter binding
proteins were identified in this experiment, to be confident about the
novel interactors I sought a reciprocal validation using ChIP-qPCR.
5.5 Validation of Nup98 as a novel pro-
tein that binds to Nanog promoter
Interestingly among the nuclear proteins that differentially bind to the
Nanog-locus in TIGR, there are 6 nuclear pore proteins, which are ex-
pected to be in the nuclear membrane. Although nuclear membrane in
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some points is connected to the chromatin, Nanog locus is not located
at the periphery of the nucleus. To verify that Nup98 may also bind
to the Nanog promoter in the ES cells I used ChIP-qPCR. Interest-
ingly this experiment not only demonstrated the binding of Nup98 to
the Nanog promoter but also indicates its preferential binding in 2iL
medium (fig. 5.4D), which is in line with the TIGR result.
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Figure 5.3: Proteins identified by targeting the Nanog promoter using
TIGR. A) Comparing proteins isolated by the Nanog probes with the
negative control. The heavy- and medium- SILAC cells were subjected
to TIGR procedure using Nanog-519 and Nanog-453, respectively; and
the light-SILAC cells was treated with the scramble probe. Proteins en-
riched significantly (adj. p-value≤0.05) in comparison to the scramble
control are shown in green. B) Comparing the TIGR results between
the two Nanog probes using the Venn diagram. C) Biological processes
related to the enriched proteins (shown in green in A and B). D) Some
of the known interactors of the Nanog promoter, detected among the
enriched proteins using the TIGR procedure.
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Furthermore, I checked fibronectin (Fn1), as a cytoplasmic candi-
date using ChIP-qPCR. Interestingly Fn1 also shows enriched on the
Nanog promoter preferentially in 2i medium. Comparing the immuno-
enrichment pattern of Nup98 with Fn1 indicates that Nup98 more
specifically binds to the Nanog promoter, while, Fn1 generally binds to
chromatin. Previously it has been shown that Nup98 binds to the
promoter of genes involved in development, cell signaling and cell
cycle-related processes [169, 170]. Although Nup98 does not have
a known DNA-binding domain it binds to chromatin, and via the
GLFG (glycine-leucine-phenylalanine-glycine) domain it is able to re-
cruit other transcription factors like CBP/P300 and histone deacety-
lases (HDACs [171, 172]). Moreover, the GLFG bodies also promote
the binding of intra-nuclear Nup98 to each other as foci, which are
called GLFG bodies [173, 174]. These studies suggest that Nup98
has a primary role as an activator of transcription [175], which ac-
cording to our data may count Nanog among its target genes. Al-
together using comparative TIGR I found several known and novel
Nanog-promoter binding proteins in addition to their dynamics on the
promoter. Among the novel candidates I selected Nup98, and for the
first time using ChIP-qPCR I could verify that it binds to the Nanog
promoter preferentially in a cellular condition that Nanog expression
has less fluctuation (2iL medium).
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Figure 5.4: Comparing proteins associated with the Nanog promoter
using the TIGR procedure. A) Proteins identified using the probe
Nanog-519 are shown in a blue to red spectrum representing 2i over
serum ratios. B) The Venn diagram shows the overlap between this
experiment and the previous experiment (shown in fig. 5.3) C) Proteins
differentially bound to the Nanog promoter are divided into two groups:
nuclear and cytosolic D) ChIP-qPCR indicates Nup98 and Fn1 bind to
the Nanog promoter, preferentially in 2i condition. prom. = promoter,
GB = gene body.
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6 Studying the effect ofNup210 on Somatic CellReprogramming
As was mentioned previously, somatic cells can be reprogrammed to
pluripotent stem cells by expressing the master or auxiliary TFs of
pluripotency such as OSKM. However, this procedure is inefficient,
and as a result of that many heterogeneous intermediate cell popula-
tions are generated. Nevertheless, some studies have tried to define
a few markers as the cornerstones of this procedure [176, 177]. These
markers are expressed sequentially among the cells that are successfully
reprogrammed to the iPS cells during a time course, which normally
takes 2 weeks. Therefore, focusing on the cells expressing the corner-
stone markers may help us to understand the mechanism of cellular
reprogramming. To this end, Hansson et. al. compared dynamics of
protein expression during the reprogramming at 6 time points based
on Thy1, SSEA1 and Oct4-eGFP expression [178]. Among the inter-
esting information obtained by this study, remarkably it turned out
that Nup210 is the only nucleoporin up-regulated during cellular re-
programming (fig. 6.1A).
As was mentioned in chapter 5, in addition to the classical roles
of nucleoporins in transportation, they have important other functions
including gene expression regulation [179]. Furthermore, recent studies
indicate cell-type specific expression of nucleoporins [180, 181]. Inter-
estingly, Nup210 is preferentially expressed in the epithelial cells dur-
ing the embryonic development [182]. Strikingly, it has been reported
that Nup210 is not detected in myoblast and mouse ESCs, however,
becomes expressed during the differentiation [183]. Furthermore, sup-
pressing Nup210 blocks differentiation by increasing apoptosis, and
decreasing the genes required for differentiation [183]. Recently it has
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been suggested that Nup210 has anti-apoptotic roles during myoblast
differentiation [184]. Nevertheless how Nup210 performs its function
has not been determined, yet.
Up-regulation of Nup210 during cellular reprogramming is another
striking observation suggesting Nup210 fulfills an important role during
dedifferentiation, which I have investigated in this chapter.
6.1 Design of the assay
For this study, I used reprogrammable mouse embryonic fibroblast
(MEF) generated by Stadtfeld et. al. [185], containing a cassette
for expressing Oct4, Sox2, Klf4 and Myc (OSKM). The cassette was
engineered in Col1a1 locus, downstream of a dox-inducible promoter.
In addition, the MEF cells are able to express reverse tetracycline-
dependent transactivator (rtTA) via another knock-in on the Rosa26
locus. Therefore, upon adding doxycycline to the medium of the MEF
cells they are able to start reprogramming without further transduc-
tion of OSKM. The advantage of this system in comparison to the
dox-inducible lentiviral system is avoiding the epigenetic silencing of
the OSKM. As a result, transgene expression is more efficient, and
homogenous among the MEF cells. Furthermore, in these MEF cells
eGFP coding sequence has been inserted into the endogenous Oct4 lo-
cus. Thus, after complete reprogramming and establishing the pluripo-
tency the endogenous Oct4 is derepressed, and eGFP is expressed as
well. As a result, the iPS colonies are eGFP positive, which is easily
distinguishable from the intermediates of reprogramming.
In order to investigate the role of Nup210 in reprogramming, I
knocked down Nup210 by two different shRNAs during the generation
of the iPS cells. Thus if Nup210 has an important role, abolishing it
should affect cellular reprogramming. To do that, shRNAs are trans-
ferred via lentiviruses produced by human embryonic kidney (HEK)
cells. Initially, HEK cells are transfected by the plasmids encoding the
shRNAs via a lentiviral vector. In addition, the other necessary genes
for the production of the viruses are transfected to the HEK cells. As
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a result, viral genome is encapsulated and secreted to the medium of
the HEK cells. The medium is collected, filtered and concentrated. To
determine the titer of the viruses, some regular MEF cells are infected.
Then the genomic DNA is isolated, and the number of integrated vi-
ral genome is determined by qPCR. Hence, the Nup210 shRNAs and
the scramble shRNA are transduced equimolar to the reprogrammable
MEF cells. Then doxycycline is added to the medium of the cells. After
2 weeks as the read-out I counted the number of Oct4-eGFP positive
colonies, and I compared it with the scramble control.
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Figure 6.1: Studying the role of Nup210 in reprogramming. A)
Expression profiling of nucleoporins during reprogramming was car-
ried out by Hansson et. al [178]. Nup210 is exclusively up-regulated.
B) In contrast to the non-targeting shRNA, using shNup210s genera-
tion of Oct4-eGFP positive (iPS) colonies is hindered; fibroblast cells
keep their identity, as they express Snail and extracellular matrix of
fibronectin. The antibody signal is green, and DAPI is blue. C) The
plot indicates the number of Oct4-eGFP positive colonies after 2 weeks.
shNup210#1: TRC101938, shNup210#2:TRC101935. D) Comparing
the mRNA expression level of epithelial and mesenchymal markers be-
tween the scramble control, and the shNup210s.
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6.2 Nup210 is required at least for the
initiation phase of reprogramming
Strikingly, knocking down Nup210 in the reprogrammable MEF cells
dramatically reduces the number of Oct4-eGFP positive colonies gen-
erated at the end of two weeks (fig. 6.1B, C). Indeed, knocking down
Nup210 by two independent shRNAs rules out the possibility of an
accidental result. Therefore, Nup210 has a critical role in successful
induction of pluripotency.
Previously, cellular reprogramming has been divided into 3 steps:
Initiation, maturation and stabilization [186]. For each step, some
markers or events have been defined. The hall mark of the initiation
phase is indeed mesenchymal to epithelial transition (MET) that can
be visualized by attenuation of mesenchymal markers such as Snail
and expression of epithelial markers such as E-cadherin. During the
maturation phase, Nanog is derepressed, and the cells are committed
to irreversible reprogramming. Finally, during the stabilization phase
pluripotency-associated markers are expressed [185].
Morphology of the Nup210 knock-down cells suggests that the cells
have not accomplished MET. To consolidate this observation, I used
immuno-staining by Snail as a TF specifically expressed in mesenchy-
mal cells. In addition, I used fibronectin as a marker highly expressed
by the fibroblast cells. As a result, immuno-staining indicates that
Nup210 knock down cells still express Snail and fibronectin. Further-
more, comparing epithelial markers such as E-cadherin and EpCAM
between the Nup210 knock down cells and the scramble control by
qPCR indicates that Nup210 knock down cells have failed to express
epithelial markers. Conversely, a mesenchymal marker like Slug has re-
mained higher in the Nup210 knock down cells. Altogether, knocking
down Nup210 clearly hinders cellular reprogramming, and the MEF
cells are not able to pass the first phase of reprogramming, quite likely
they retain their fibroblast identify despite expressing OSKM for 2
weeks.
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6.3 Nup210 is needed for normal prolif-
eration of the MEF cells
To investigate further why Nup210 is required for MET, I knocked
it down in the MEF cells with and without the induction of OSKM.
In both cases comparing the growth curves with the scramble con-
trol clearly indicates that the cells do not proliferate normally as a
result of Nup210 suppression. Without expressing OSKM, the cells
stop proliferating, whereas, expression of OSKM up-regulates Nup210,
and to some extent alleviates cellular senescence. Therefore, Nup210
is needed for normal proliferation of the MEF cells. Interestingly, it
has been previously shown that rapid proliferation is essential for the
induction of pluripotency, conversely, cell cycle arrest inhibits success-
ful reprogramming [187]. Thus knocking down Nup210 inhibits normal
proliferation of the cells, and consequently OSKM are unable to push
the cells toward an epithelial identity, hence, cellular reprogramming
fails in the initiation phase.
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Figure 6.2: The growth curve of the MEF cells after the suppres-
sion of Nup210. A) The growth curve of the MEF cells transduced
with shNup210 and the scramble shRNA are shown in blue and red,
respectively. Doxycyline was not added to the medium of the cells. B)
Doxycycline was added to the medium of the MEF cells to induce the
expression of OSKM. Dramatic up-regulation of Nup210 (based on fig.
6.1A), alleviates the effect of shNup210.
Interestingly, TIGR results (chapter 5) suggest Nup210 is a Nanog
promoter-associated protein. Additionally, SICAP (chapter 3) using
the mouse ES cells indicates that Nup210 is a chromatin-associated
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protein. Although nucleoporins traditionally have been considered as
nuclear transporters, recent studies have revealed their roles in the
maintenance of genome integrity, and DNA repair. For instance, Nup84
is involved in relocation of Double-strand DNA break to the nuclear
periphery, which probably assists the repair process [188]. Further-
more, telomeric chromatin is protected by binding to the Mlp1 and
Mlp2 nucleoporins via Yku70/Yku80 complex [189, 190]. Unprotected
telomeres eventually arrest cell cycle [191, 192]. Additionally, riboso-
mal DNA (rDNA) repeats are associated to the nuclear envelope via
CLIP proteins, which are critical for the stability of the chromatin
loops at these loci [193, 194].
Altogether, Nup210 is a chromatin-associated protein that is es-
sential for cell proliferation, and iPS generation. The mechanism by
which Nup210 affects cell cycle, whether by DNA replication or other
pathways, remains to be elucidated further.
70
7 Discussion
By comparing chromatin-associated proteins between two cellular states
it should be possible to understand how the cells are able to change
their transcriptional programs in order to establish a new phenotype.
However, due the complexity of chromatin, studying the DNA-bound
proteins has been challenging. Although ChIP-seq has provided valu-
able information about the genome-wide occupancy of one protein in
each experiment, it is blind to other chromatin-associated proteins. To
identify chromatin-bound proteins in an unbiased manner, the avail-
able methods are not solid enough to rule out the artifacts and con-
taminants associated with the isolation of chromatin. For example,
nuclei and the chromatin fraction are commonly isolated based on the
large size and insolubility, respectively. However, using these proce-
dures many unexpected proteins such as ribosomal proteins or growth
factors are identified as well. Therefore, it is hard to exclude that
they are contaminants from the endoplasmic reticulum (ER), as the
membrane of the nuclei and the ER are fused together. Even for a
canonical chromatin-binding protein it is hard to distinguish between
the chromatin-bound fraction and the soluble pool in the nucleosol.
7.1 Specific in-vitro labeling of in-vivo fixed
chromatin
Here I have aimed to develop novel methods for studying dynamics
of chromatin-associated proteins globally, and in a protein-targeted
fashion by SICAP and ChIP-SICAP, respectively. I have demonstrated
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the power of these methods by studying chromatin composition in the
ES cells, and by comparing the ground-state and the metastable state
of pluripotency to identify multiple known as well as novel proteins
involved in the maintenance of pluripotency.
Firstly, I used formaldehyde cross-linking and sonication as it is
conventionally used in ChIP, therefore, it is unlikely that too many
proteins are cross-linked to the chromatin, as the validity of ChIP re-
sults with formaldehyde cross-linking has already been demonstrated
[195]. Furthermore, after the sonication I spun the sheared chromatin
to sediment the large molecular complexes and cell debris. As a re-
sult, chromatin and other cellular complexes are fragmented into small
fragments.
The key benefit of SICAP and ChIP-SICAP methods resides in the
TdT-mediated biotinylation of sheared DNA, thereby specifically label-
ing DNA. Capture on streptavidin beads facilitates stringent washing,
providing distinct advantages over centrifugation-based and contamination-
prone chromatin-precipitation. The benefit of ChIP-SICAP over mChIP
[108], ChIP-MS[109], ChroP[110] and RIME[196] resides in the subse-
quent enrichment of the bait protein and DNA (essentially constituting
a DNA-based pull-down) formally proving that the target protein and
its partners bind to chromatin. Additionally, by removing the back-
ground proteins, including the antibody and protein A/G, the ratio of
signal to noise is enhanced, and false negatives/positives are dramat-
ically reduced. As a result, ChIP-SICAP works with a substantially
reduced number of cells (20 million) in comparison to mChIP (10 bil-
lion), ChIP-MS (1 billion) and ChroP (100 million).
Importantly, ChIP-SICAP revealed that proteins co-localized on
the chromatin are quite different to the soluble interactants. Indeed,
this observation has not been feasible previously, as the previous affinity-
capture methods are not able to distinguish between the chromatin-
bound proteins and soluble interactants. Thus using ChIP-SICAP we
are able to identify novel partners for a protein that are functionally
more relevant to the chromatin-linked roles of the target protein.
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7.2 Dynamics of chromatin-associated pro-
teins in the ground-state and metastable
states of pluripotency
The ability of SICAP to determine changes in chromatin composition
revealed that chromatin is highly dynamic, evidenced by the large num-
ber of proteins preferentially associating to DNA in either 2iL or serum
conditions (fig. 3.3A). Furthermore, dynamics of chromatin-binding
does not necessary follow the changes at the expression level of a given
protein. For instance, Uhrf1, required for the maintenance of 5mC,
is only significant based on SICAP data in serum condition, which is
supported by the fact that DNA methylation is higher in the same
condition [24, 89]. Moreover, Scml2, a polycomb-associated protein,
does not show significant changes in its total level of expression, while
the chromatin-binding in 2i condition is indeed significant. Consider-
ing that DNA is hypomethylated in 2i condition, the SICAP result is
in line with a recent study that has shown Scml2 association to chro-
matin upon hypomethylation of DNA[112]. Taken together, dynamics
of chromatin-binding revealed by SICAP is more influential in compar-
ison to the full proteomics in terms of understanding the mechanism
of transcriptional regulation.
Furthermore, using ChIP-SICAP it turned out that several key
pluripotency factors such as Tbx3, Stat3, Sall4, Esrrb and Zfp42 (Rex1)
show enhanced chromatin interaction in the ground state of pluripo-
tency, however, without a change in their overall expression level. This
observation may provide an explanation for how 2i medium provide
a better condition for culturing ES cells. Additionally, based on our
result Tcf3 binds to the chromatin upon the activation of the Wnt path-
way. Therefore, our result supports the model that ß-Catenin converts
Tcf3 from an inhibitor complex to an activator of OSN [87], rather
than wiping it out [86].
Strikingly SICAP revealed that the growth factor Fgf4 binds to
chromatin especially in 2iL condition. Interestingly we showed that
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HA-tagged Fgf4 secreted from HEK293 cells can translocate to the nu-
cleus of ES cells. Although this is an unknown property of Fgf4, studies
on the mechanism of nuclear import of Fgf1[197] and Fgf2[198] have
identified cytosolic interactors and karyopherins to mediate transport
through the nuclear pore. Although we can only speculate on the func-
tion of chromatin-bound Fgf4, it is at least striking that PD0325901,
one of the 2iL inhibitors, inhibits Fgf4 signaling to prevent differen-
tiation. As a result, we observe massive up-regulation of Fgf4 in 2i
medium (>20-fold). One explanation is that excessive Fgf4 may be con-
fined in the nucleus to avoid over activation of the signaling pathway.
Clearly, further studies will be required to investigate this unexpected
trait of Fgf4, which should include ChIP-seq to determine genome-wide
occupancy. Experiments in this direction failed in our hands because of
the lack of a ChIP-grade antibody. Moreover, I have tried to generate
a stable cell line for expressing Fgf4 fused with the HA-tag, however,
over-expressing Fgf4 leads to significant differentiation of the ES cells
even in 2iL medium.
7.3 Reciprocal validation of SICAP and
the antibody using ChIP-SICAP
By design ChIP-SICAP targets the chromatin-bound fraction of the
bait protein and proteins that bind in its vicinity. After mass spec-
trometry, for all tested targets (Oct4, Sox2, Nanog, Suz12 and Dazl)
this resulted in a typical pattern ranking core histones as the most
abundant proteins, followed by the bait protein. Histones are expected
from the fact that ChIP-SICAP investigates native chromatin, how-
ever, histones have normally not been detected by affinity purification
of OSN. Identification of the bait protein provides an independent vali-
dation of the antibody and its ability to pull down the bait under ChIP
conditions. Thereby ChIP-SICAP follows the recommendations that
were recently proposed for the quality-control of antibodies in affin-
ity purification strategies[199]. Finally, typically dozens to hundreds
of proteins follow at lower intensities, which we interpret as proteins
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that co-localize with the bait at a decreasing number of genomic loci.
These proteins do not necessarily physically interact with the bait pro-
tein, but are co-isolated on the same DNA fragment. Considering that
chromatin was sheared to an average size of 200 bp, this still implies
close protein spacing to facilitate functional cross-talk.
Additionally, ChIP-SICAP procedure is a proof of chromatin-binding
for a protein of interest. In fact, observing the histones on top of the
protein intensities followed by the target protein, verifies chromatin-
binding of the target protein. Therefore, the unexpected proteins
identified by SICAP can be further consolidated by ChIP-SICAP. As
an example, using this approach I could demonstrate that Dazl is a
chromatin-binding protein, which co-localizes with several other pro-
teins with the ability to bind to DNA and RNA. This observation
suggests that post-transcriptional regulations are started right away
from the chromatin.
It is noteworthy that the result of ChIP-SICAP indicates proteins
co-localized with the bait protein on many genomic loci, however, these
co-localizations should be repeated frequently enough to provide the
mass spectrometer with enough material to identify the peptides. In
other words, the identified proteins are among the typical co-localizers
of the bait protein over many genomic loci. Thus proteins identified
by the ChIP-SICAP procedure are potentially good candidates to be
verified for binding to the locus of interest.
7.4 Expanding the core-transcriptional cir-
cuitry of pluripotency
Using ChIP-SICAP we identified about 400 proteins that co-localized
with all 3 core factors Nanog, Oct4 and Sox2 (OSN) reflecting high
inter-connectivity most likely at multiple genomic loci. The tight clus-
tering of novel proteins among these well-established components of
the core-circuitry prompted us to validate Trim24, an ubiquitin lig-
ase targeting p53 for degradation[200]. ChIP-seq not only confirmed
association of Trim24 to the OSN network, but also showed that it fre-
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quently did so at super-enhancers co-occupied with p53 near Nanog,
Sox2, Tbx3 and Prdm14 loci. This may explain how p53 is restrained
within the core-circuitry to safeguard pluripotency in 2iL medium. In-
deed, the important role of Trim24 in the development of blastocyst,
and activation of embryonic transcription has been previously demon-
strated[201].
Indeed, one of the questions in the field is that how 2i ES cells
can survive while Myc is dramatically down-regulated in 2i condition
( 30-fold). Here we observe that Trim24 co-localizes with OSN on the
enhancers of the genes related to cell proliferation such as Kit, MycN,
FoxP1, Mdm4, Gli2 and Kras. Therefore, it is conceivable that in the
absence of Myc, Trim24 positively regulates the cell proliferation, as it
is a potent oncogene in breast cancer[202], [203].
7.5 Toward identification of locus-specific
associated proteins
Although ChIP-SICAP is a robust method, it needs a good antibody
for the target protein. Indeed, identification of proteins associated with
a locus of interest would be more straight-forward if we could capture
the given locus by oligonucleotide probes. In other words, in this case
the aim of the method is exactly complementary to that of ChIP. Pre-
viously Dejardin and Kingston have tried to achieve this aim by LNA
probes using a method called PICh[111], however, this method has so
far remained limited to the repetitive regions with many copies per cells
[111, 112, 204]. Likewise, Kennedy-Darling used the same strategy to
identify proteins associated with rDNA, telomeric X-element, and Gal
1-10 in yeast[205]. However, the efficiency of recovering the target is
only about 1%. Here I have aimed to improve this strategy by modify-
ing the hybridization of the probe using alkaline conditions instead of
neutral pH. Starting from a self-invented protocol, I called this proce-
dure as TIGR. Evaluated by qPCR and high-throughput sequencing,
the hybridization is quite efficient and specific (about 15% to 20% in
the case of Nanog promoter). Remarkably several TFs and chromatin
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proteins known to associate with the Nanog promoter have been iden-
tified using TIGR. Being verified independently by ChIP-qPCR, for
the first time I could demonstrate that Nup98 binds to the Nanog pro-
moter. These results all promising that TIGR method is a powerful
and generalizable tool to identify proteins that interact with individual
genomic loci whose functionality may have been suggested by genetic
or computational approaches, but whose biochemical composition may
now be unraveled by TIGR.
7.6 Conclusion
Throughout this thesis, three novel methods were invented for study-
ing chromatin protein composition. Firstly, SICAP was presented
for studying global composition and dynamics of chromatin-associated
proteins. Using this method DNA-protein complexes are specifically
labeled in an enzymatic reaction by TdT to be purified. This approach
was used for the first time in the field. This opens up the way for un-
biased identification of unknown chromatin complexes, many of which
have been ignored due to the lack of a specific method in the field. Ad-
ditionally, proteins with subtle changes in their expression levels are
commonly ignored in studying biological systems, however, thanks to
SICAP I have shown that some of these proteins bind to chromatin sig-
nificantly, which is quite important from transcriptional and epigenetic
point of view.
Secondly, I combined ChIP and SICAP to focus on the chromatin-
bound partners of a protein of interest. This combination provides a
solution for shortcomings in previous methods such as mChIP, ChIP-
MS, ChroP and RIME. Indeed, thanks to the molecular mechanism
of ChIP-SICAP we can confirm that the identified proteins are bound
to chromatin. Furthermore, ChIP-SICAP provides the most specific
validation of SICAP. Considering that DNA-labeling is carried out in-
vitro, SICAP and ChIP-SICAP can be generically applied to any cell
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culture system as well as tissues.
Thirdly, I developed and applied TIGR for targeting the Nanog
promoter by regular oligonucleotides probes. At the present time, I’m
in the process of expanding this method to other loci and different
species in order to evaluate the accuracy of the results, and possibly
to improve the method.
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8 Material and Methods
8.1 Cell culture and cell fixation
46c mouse ES cells were grown feeder-free on 0.2% gelatinized cell cul-
ture plates in either traditional ES medium with serum or 2i medium.
The serum medium contained DMEM high glucose (Life technologies,
11965-092) supplemented with 15% fetal bovine serum (Life technolo-
gies, 10270-106), 100 µ M MEM non-essential aminoacids (Life tech-
nologies, 11140-050), 1xGlutamax (Life technologies, 35050-061), 1x
penicillin and streptomycin (Life technologies, 15140-122), 100µM of
2-mercaptoethanol (Sigma, M7522), and 200ng/ml of LIF (EMBL, pro-
tein expression core facility). The 2i+LIF (2iL)-medium contained
DMEM/F12 medium for SILAC (Pierce, 88215), 100µMMEM non-
essential aminoacids (Life technologies, 11140-050), 1xGlutamax (Life
technologies, 35050-061), 1x penicillin and streptomycin (Life tech-
nologies, 15140-122), 100µM of 2-mercaptoethanol (Sigma, M7522),
0.5mg/ml of BSA (Sigma, A3059), 200ng/ml of LIF (EMBL, protein
expression core facility), 1µM of PD0325901(Reagents Direct, 39-C68),
3µM of CHIR99021 (Reagents Direct, 27-H76). In addition, for light
SILAC, 100 mg/ml of Lysine (L8662), 100 mg/ml of Arginine (Sigma,
A6969) and 100 mg/ml of Proline (Sigma, P5607) were added to the
2i medium. For Heavy SILAC 100 mg/ml of 13C6,15N2-L-Lysine
HCl (Silantes, 211604102), 100 mg/ml of 13C6,15N4-L-Arginine HCl
(Silantes, 201604102) and 100 mg/ml of Proline (Sigma, P5607) were
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added to the 2iL-medium. For cell fixation, the cells were harvested by
Stempro Accutase (Life technologies, A11105-01), and spun 5min at
200g to remove the medium. Then the cell pellet was resuspended in
1.5% formaldehyde (Pierce, 28906) in PBS. After 15 min incubation at
room temperature with occasional rotations, 125mM Glycine (Merck,
56-40-6) was added to the solution to quench cross-linking. Then the
cells were washed twice with PBS, counted and aliquoted, and stored
at -80◦C as dry cell pellets.
8.2 SICAP
About 4 million fixed ES cells were used per condition and replicate.
The cells were resuspended in 900 µl TE buffer plus Complete protease
inhibitor (Roche, 11873580001), and kept on ice for 5min. Then 100
µl Triton X-100 10% was added, and the cells were incubated another
5min on ice. Cells were washed twice by resuspending them in 10mM
Tris-HCl (pH = 7.5), spinning afterward at 500g for 5min, and remov-
ing the supernatant. Cells were sonicated in 130 µl of 10mM Tris-HCl
using CovarisS220 for 430 seconds by Duty cycle: 10%, Intensity: 5
and Cycle/Burst: 200 to shear chromatin to an average size of 200 nu-
cleotides, followed by centrifugation at 12000g for 10min to sediment
cell debris, and collection of the supernatant. Then 30 µg of RNase A
(Life technologies, EN0531) was added to the clear supernatant, and in-
cubated at 37◦C for 30min. Then the sheared chromatin of the heavy
SILAC sample was mixed with 1xTdT buffer, 50 µM of Biotin-11-
ddUTP (Jenabioscience,NU-1619-BIOX) and 60U of TdT (Life tech-
nologies, EP0161) to biotinylate DNA, while the sheared chromatin
of the light SILAC (negative control) sample was mixed with 1xTdT
buffer and 60U of TdT leaving out Biotin-11-ddUTP. The samples were
incubated at 37◦C for 30min with 1000 RPM agitation. To solubilize
the precipitated sheared chromatin, 252 µl Ampure XP (Beckman,
A63880) was added to the suspension. After mixing and incubation
at room temperature for 5min, the beads were adsorbed by a magnet,
and the supernatant was removed. Then 700µl ethanol 70% (v/v) was
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added to the beads on the magnet without resuspending them. The
ethanol was removed, and this step was repeated once again. After
that Tris-HCl 10mM was added to the beads to eluted DNA, and they
were resuspended by a short sonication. The beads were then removed,
and the supernatant was collected. Then heavy and light SILAC sam-
ples were mixed, and 1% SDS was added to the sheared chromatin.
The volume was adjusted to 1.5ml with IP buffer (Tris-HCl 50mM pH
= 7.5, Triton X100 1%, NP40 0.5%, EDTA pH= 8 5mM and NaCl
150mM). Then 50 µl Streptavidin beads (NEB, S1420S) were added to
the solution. After 30min rotation head-to-tail, the beads were succes-
sively washed 3times with 1% SDS, once with 2MNaCl, twice with 20%
iso-propanol, and 5 times with 50% acetonitril. The beads were then
resuspended in 0.1% RapiGest (Waters, 186001861) and 5mMDTT. To
reverse the cross-links, the beads were boiled at 95◦C for 20min. Fi-
nally, the beads were removed, and 10mM iodoacetamide was added to
the solution. After 30min incubation, again 5mM DTT was added to
the solution. Then 100ng Lys-C (Wako, 125-05061) and 500ng Trypsin
(Promega, V5280) were added to the samples to digest the proteins.
To compare chromatin protein composition, 4 million ES cells grown
in heavy SILAC 2iL medium were mixed with 4 million ES cells grown
in serum medium and processed as described above.
8.3 ChIP-SICAP
Sheared chromatin was prepared as described above, however from 24
million ES cells. After sedimentation of the cell debris by spinning, the
antibody was added to the sheared chromatin obtained from the heavy
SILAC sample, while to the light SILAC sample no antibody was added
to serve as a negative control. After an overnight agitation at 4◦C, the
samples were spun at 12000g for 10min. Then 90% of the solution was
collected and the volume was adjusted to 1ml with the IP buffer. Then
30µl Dynabeads protein A or protein G (Life technologies, 10001D or
10003D, respectively depending on the antibody) were added to the
samples. Following 2 hours of rotation, the beads were washed once
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with 10mM Tris-HCl, and once with 1xTdT buffer. Then the beads
were resuspended in 1xTdT buffer, 60 U of TdT and 50µM of Biotin-
11-ddUTP, and incubated at 37◦C for 30min. Subsequently the beads
were washed 6 times with ice-cold IP buffer, resuspended in 200mM of
DTT and 7.5% of SDS, and incubated at 37◦C for 30min. Then the
beads removed on the magnet, and the solution was collected. At this
point the heavy and light labeled samples were mixed, and the volume
was adjusted to 1.5ml by IP buffer. Then 50 µl of Streptavidin beads
were added, and the samples were rotated 30min at room temperature.
Then the beads were washed, and proteins were digested as described
in the SICAP procedure. To compare proteins co-localized with the
bait protein in 2iL and serum media, 24 million ES cells grown in
heavy SILAC 2iL medium were mixed with 24 million ES cells grown
in serum medium with natural aminoacids. The rest of the procedure
was performed as described above.
8.4 TIGR
In this experiment the Nanog promoter was targeted by two specific
probes with the following sequences:
Nanog-519: CTTGACCTGAAACTTCCCACTAGAGATCGCCAGGG
TCTGGAGGTGCA
Nanog-453: AGGTGCAGCCGTGGTTAAAAGATGAATAAAGTG
AAATGAGGTAAAGCCTCTT
In addition, a non-targeting probe with the following sequence was
used as a negative control:
Scram: AGGTGCAGCCGTGGTTAAAAGATGAATAAAGTGAAAT-
GAGGTAAAGCCTCTT
All probes were biotinylated at the 5’-end via a linker called triethyleneg-
lycol (TEG). About 24 million cells per probe. Probe Nanog-519 was
applied to the heavy SILAC cells, Nanog-453 was applied to the in-
termediate SILAC cells, and Scram was applied to the light SILAC
cells. The cells were split into 6 microtubes (4 million cells per tube).
The cells in each tube were resuspended in 300 µl of IP buffer, and
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5µl RNase A (10 mg/ml, Fermentas EN0531) was added to each tube.
Then the tubes were incubated at 37 ◦C for 15-30 min. After that 500
µl of DNAzol (Life technologies, 10503-027) was added to the tubes.
Then the tubes were vortexed vigorously for a few seconds, and the
spun at 5000g for 2min. The supernatant was discarded, and the pel-
let was resuspended again in 500 µl of DNAzol. Once again, the tubes
were vortexed vigorously for a few seconds, and the spun at 5000g for
2min. The supernatant was discarded, and each tube was resuspended
gently in 300µl of NaOH 25mM. Then the samples were incubated at
37 ◦C for 30 min, without agitation. After that, the tubes were son-
icated using Bioruptor Plus (Diagenode), 14 cycles in the high mode,
30 seconds on, 30 seconds off. Then 1ul of the diluted the relevant
probe (1 pmol/µl) was added to each tube, and the content of the
tube was applied to an Amicon ultrafiltration column (30kD, Milli-
pore, UFC503096). The columns were spun 5 min at 12000g, and then
300 µl of BW buffer (Tris-HCl 10mM pH=7.5, EDTA 1mM, NaCl 1M)
was added to the column. Again columns were spun 10 min at 12000g
to reduce the volume to about 100ul. After that the liquid was col-
lected, and poured into a 2-ml Eppendorf tube with 300 µl of BW
buffer. Then the tubes were incubated at 65 ◦C for 5 min, 600 µl of
BW buffer was added to each tube. After that the content of 3 tubes
with heavy SILAC samples, 3 tubes with medium SILAC samples and
3 tubes with light SILAC samples were mixed in a 15 ml-Falcone tube
(2 Falcone tubes, 9ml in each tube). Then 50ul of Streptavidin mag-
netic beads (NEB, S1420S) was added to each tube, and the tubes
were rotated for 1-hour head to tail. After that the beads were washed
2 times with 10 ml of SDS wash buffer-1 (Tris-HCl 10mM pH=7.5,
EDTA 1mM, NaCl 350 mM, SDS 0.5%); once with 10 ml of SDS wash
buffer-2 (Tris-HCl 10mM pH=7.5, EDTA 1mM, NaCl 200 mM, SDS
1%); two times with 10 ml of iso-propanol wash buffer (2-propanol
20% in water (v/v), NaCl 500mM); four times with 10 ml of acetoni-
trile wash buffer (acetonitrile 40% in water (v/v), NaCl 500mM). Then
beads were resuspended in 0.8 ml of the acetonitrile wash buffer, and
transferred to a 2-ml Eppendorf tube. Finally the acetonitrile wash
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buffer was discarded and the beads were digested The beads were then
resuspended in 0.1% RapiGest (Waters, 186001861) and 5mM DTT.
To reverse the cross-links, the beads were boiled at 95◦C for 20min. Fi-
nally, the beads were removed, and 10mMiodoacetamide was added to
the solution. After 30min incubation, again 5mM DTT was added to
the solution. Then 100ng Lys-C (Wako, 125-05061) and 500ng Trypsin
(Promega, V5280) were added to the samples to digest the proteins.
8.5 High pH fractionation and mass spec-
trometric analysis
Following digestion of the proteins, the peptides were cleaned up using
stage-tipping procedure [206]. In order to confine streptavidin peptides
into discrete fractions in order to minimize interference with MS detec-
tion of genuine prey peptides, the samples were subjected to fraction-
ation using high pH reversed-phase chromatography. Peptides were
fractionated on an Agilent 1200 Infinity HPLC system with a Gem-
ini C18 column (3 µm, 110 Å, 100 1.0 × mm, Phenomenex) using a
linear 60 min gradient from 0% to 35% (v/v) acetonitrile in 20 mM
ammonium formate (pH 10) at a flow rate of 0.1 ml/min. Elution of
peptides was detected with a variable wavelength UV detector set to
254 nm. Thirty two1-min fractions were collected that were subse-
quently pooled into ten fractions using a post-concatenation strategy
as previously described. Each fraction was then analyzed using LC-
MS on a Orbitrap Velos Pro (Thermo Fisher Scientific) connected to a
nanoAcquity UPLC via a nanoelectrospray ion source (Waters). Pep-
tides were separated with a BEH300C18 (75 µmx 250 mm, 1.7 µm)
UPLC column (Waters) using a stepwise 60-min or 240-min gradi-
ents, respectively depending on ChIP-SICAP or SICAP from 3% to
85% (v/v) acetonitrile in 0.1% (v/v) formic acid at a flow rate of 300
nl/min. The LTQ-Orbitrap Velos Pro mass spectrometer was operated
in data-dependent mode, acquiring one survey MS scan in the orbitrap
followed by up to 15 fragmentation scans (TOP15) of the most abun-
dant ions analyzed in the LTQ by CID fragmentation. Only charge
84
CHAPTER 8. MATERIAL AND METHODS
states of two and higher were allowed for fragmentation. Essential
MS settings were: full MS: AGC = 106, maximum ion time = 500
ms, m/z range = 375–1600, resolution = 30 000 FWHM; MS2: AGC
= 30 000, maximum ion time = 50 ms, minimum signal threshold =
1500, dynamic exclusion time = 30 s, isolation width = 2 Da, nor-
malized collision energy = 40, activation Q = 0.25. The MS spectra
were analyzed using Proteome Discoverer 1.4 (Thermo Fisher Scien-
tific), and the proteins were identified using MASCOT search engine
(Matrix Science) against the Mus musculus proteome of the Uniprot
database. The Perculator algorithm [207] was used to limit FDR rates
to a q-value<0.01
8.6 ChIP-seq
Shearing chromatin and IP were performed as described above for
ChIP-SICAP, however omitting the DNA-labeling. In addition, an
aliquot was taken from the clear sheared chromatin to be used as an
input control. After the IP and six rounds of washing steps with the
ice-cold IP buffer, the beads were resuspended in TE buffer plus 1%
of SDS. Then the samples were boiled at 95◦C for 20min, and 40µg
proteinase K was added for protein digestion at 55◦C for 30min. Next
DNA was purified using phenol/chloroform isoamylalcohol and precip-
itated using glycogen and ethanol. Finally, DNA was resuspended in
30µl of Tris-HCl 10mM. To prepare the library for Illumina sequencing,
purified ChIP DNA was end-repaired by Klenow, T4 DNA polymerase
and T4 polynucleotide kinase. Then DNA fragments were subjected to
A-tailing, and NEBNext adapter ligation (NEB Index Primers Set 1,
E7335S). Following PCR for 12 cycles, the amplicons were size-selected
by mixing 50µl PCR products with 30µl of Ampure XP beads. The
supernatant was collected, and again 45 µl of AmpureXP beads was
added. After 2 rounds of washing with 70% ethanol, the DNA was
eluted in 50µl of Tris-HCl 10mM. Once again the eluted DNA was
mixed with 48µl of AmpureXP beads, and after the washing, they
were eluted by 15 µl of Tris-HCl 10mM. Sequencing was carried out by
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Illumina HiSeq 2000 according to the manufacturer’s protocols.
8.7 ChIP-seq data analysis
Unless stated otherwise, analysis was performed in a local installa-
tion of Galaxy [208-210] maintained by the EMBL Genome Biology
Computational Support. The 50-bp single-end reads were aligned to
build version NCBI37/MM9 of the mouse genome using Bowtie ver-
sion 2.0 [211] using standard options (Galaxy Tool version 0.2, sensitive
preset). Reads failing to be mapped or mapping at several locations
(as identified by the XS tag set by bowtie2) were removed using the
“Filter SAM” tool and the “Select” tool, respectively. Read dupli-
cates where identified and removed using Picard’s Mark Duplicates
(http://broadinstitute.github.io/picard). Sequencing data quality was
assessed using FastQC and the Deeptools package[212]. ChIP qual-
ity was estimated by cross-correlation using the “SPP” tool as sug-
gested by ENCODE ChIP-seq guidelines[213]. Finally, reproducibility
of ChIP replicates and final peak selection was achieved using the IDR
pipeline of Landt et. al.[213], and implemented following instructions
from https://sites.google.com/site/anshulkundaje/projects/idr.
We used MACS version 2 [214] as the underlying peak caller with
recommended options (i.e. setting p-value cutoff to 1e-3). The final
list of peaks used in the study corresponds to the “optimal” list (i.e.
using peak called on merged replicates) at a 2% IDR cutoff. Heatmaps
were produced using the Deeptools computeMatrix and heatmapper
tools on input-subtracted coverage files (see below). Coverage files
(bigwig format) were generated using the Deeptools bam Coverage
tool using the “Normalize coverage to 1x” option. Input subtraction
(from ChIP signal) was performed using the Deeptools bigwig Compare
tool. An average fragment size of 200 bp and bin sizes of 50 bp was
systematically used. The annotation of the peaks and the nearby genes
were carried out using the R package ChIPseeker [215].
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8.8 List of the antibodies used for the IP
Nanog (D2A3) XP Rabbit mAb (Cell Signaling Tech, 8822 S)was ap-
plied 1:100 (v/v) to the sheared chromatin obtained from 24 million
cells for the ChIP-SICAP assay. Oct-4A (C30A3C1) Rabbit mAb (Cell
Signaling Tech, 5677 S)was applied 1:50 (v/v) to the sheared chromatin
obtained from 24 million cells for the ChIP-SICAP assay. Human
SOX2 Affinity Purified Polyclonal Ab (R&D Systems, AF2018)25µg
was applied to the sheared chromatin obtained from 24 million cells
the ChIP-SICAP assay. E-Cadherin (24E10) Rabbit mAb (Cell Sig-
naling Tech, 3195s) was applied 1:50 (v/v) to the sheared chromatin ob-
tained from 24 million cells for the ChIP-SICAP assay. Dazl antibody
(Cell Signaling Tech, 8042 S) was applied 1: 50 (v/v) to the sheared
chromatin obtained from 24 million cells for the ChIP-SICAP assay.
Trim24/TIF1a antibody (Bethyl lab, A300-815A) 2.5 µg was applied to
the sheared chromatin obtained from 24 million cells for the ChIP-Seq
assay. Mouse Monoclonal Fgf4 antibody (R&D systems, MAB58461)
was used for immuno-fluorescent microscopy; diluted 1:200 in BSA 1%
in PBS-T. HA-tag (C29F4) Rabbit monoclonal antibody (Cell Signal-
ing Tech, 3724S) was used for immuno-fluorescent microscopy; diluted
1:500 in BSA 1% in PBS-T. Anti-rabbit IgG conjugated with Alexa
Fluor 555 (Cell Signaling Tech, 4413S) was used as the secondary anti-
body for immuno-fluorescent microscopy; diluted 1:500 in BSA 1% in
PBS with 0.1%Tween20. Anti-rat IgG conjugated with Alexa Fluor 488
(A-11006) was used as the secondary antibody for immuno-fluorescent
microscopy; diluted 1:500 in BSA 1% in PBS with 0.1%Tween20 .
8.9 GO analysis
Annotations of the genes were determined either using Perseus soft-
ware[216], or were downloaded directly from Uniprot database. Addi-
tionally sub-cellular localizations based on HPA antibodies were down-
loaded from the website: http://www.proteinatlas.org/; GO biological
processes and their enrichments were determined using DAVID bioin-
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formatics resources[217]
8.10 HPA antibodies and immuno-fluorescence
In this study, 159 primary antibodies validated within the Human Pro-
tein Atlas (HPA) project [126] were selected that detect proteins en-
coded by 134 different genes in Human cells. The antibodies were
selected either by a high sequence similarity (>49%) in the antigenic
region of the human and murine orthologs or show a high similarity in
the staining of human and murine cell lines, respectively.
Immuno-fluorescent stainings were prepared in 96-well glass bottom
plates (Greiner Bio-One, 655891) coated with gelatin. 30000 mES cells
cultivated in 2i medium were seeded per well and incubated for 24h.
Cell fixation, permeabilization, and immuno-fluorescent staining were
performed according to the standard protocol at the HPA [218]. Briefly,
cells were washed with PBS prior fixation for 15 min with 4% ice-cold
paraformaldehyde in growth medium supplemented with 10% FBS or
in PBS, and permeablized with Triton X-100 in PBS for 15 minn. The
cells were then incubated with the primary antibodiee, and/or anti-
alpha-Tubulin (Abcam, ab7291) diluted according to the provider’s
recommendation overnight at 4 ◦. After 3-5 washing with PBS, the cells
were incubated with the secondary antibodies for 1-1.5h. Following a
nuclei-statining with DAPI for a few min. After 5 washing, the wells
were filled with PBS and/or glycerol.
8.11 Treating the ES cells with the HA-
tagged Fgf4
Fgf4 cDNA was amplified by PCR using the Forward primer:
5’-TTTGGATCCGCCACCATGGCGAAACGCGGGCCGA-3’
and the reverse primer:
5’-TTTGTCGACTCAGGCATAGTCAGGCACGTCATAAGGATATC
CCAGTCTAGGAAGGAAGTG-3’.
In fact the reverse primer contained the HA-tag coding sequence. The
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PCR product was digested by BamHI and SalI, and then it was cloned
into pLV-mCherry (pLV-mCherry was a gift from Pantelis Tsoulfas,
Addgene plasmid # 36084) using the same enzymes instead of mCherry.
The coding sequence was then confirmed by Sanger sequencing. Sub-
sequently HEK293T cells were transfected by pLV-Fgf4, psPAX2, and
VSV-G. To do that, 8 million cells were seeded in a T75 flask, after
an overnight incubation the cells were transfected using FuGENE HD.
After 8 hours the medium of the cells were changed with the fresh one.
About 2 days after the transfection, the virus-containing medium was
collected, filtered, and concentrated using Amicon 100kD ultrafilter-
ation tubes. The concentrated medium was used to infect a new batch
of HEK293T cells. The transduced HEK293T cells were expanded to
a 10cm dish. When the cells became confluent, the medium of the
cells was replaced with the medium containing 1% FBS for 24 hours.
Then the medium was collected, filtered, and concentrated by Ami-
con ultrafilteration tube 3kD from 10ml to 0.5ml. The ES cells were
seeded in a 96-well plate using 2i medium. During the seeding 20ul
of the concentrated HA-Fgf4 was added to the medium of the cells.
After 24 hours, again 20ul of the concentrated HA-Fgf4 was added to
the medium of the cells. Finally, after 2 hours, the cells were fixed us-
ing formaldehyde 4%, and subjected to immuno-fluorescent microscopy
using anti-HA antibody as described previously.
8.12 Nup210 knockdown
As it has been previously published [178], HEK293T cells were trans-
fected by psPAX2, VSV-G and a lentiviral vector: Nup210 shRNAs
(TRCN0000101935 or TRCN0000101938), pLKO.1 scrambled shRNA
or the mock vector. One overnight after the transfection, the medium
of the cells were changed with the fresh medium with1%FBS. About
2 days after the transfection, the medium of the cells were collected,
filtered, and concentrated by Amicon ultra-15 centrifugal filter unit
100kD. Then regular MEF cells were infected with different volumes
of the concentrated viruses to measure the integration copy number
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of the viruses into the genome of the host cells by quantitative PCR,
hence, the titer of viruses was calculated for the next step. The primer
sequences were as follows:
primer name sequence (5’-3’)
Rpph1-F AGTCTGAATTGGGTTATGAGG
Rpph1-R AGGTGAGTTCCCAGAGAGCA
pLKO-F GAATAGTAGACATAATAGCAACAGAC
pLKO-R CCAAAGTGGATCTCTGCTGTC.
About 106 reprogrammable MEF cells [185] in passage 2 were split
into a 6-well plate. The day after seeding, the medium of the cells
were changed with the fresh one plus 4 mg/ml polybrene, and the
cells were infected with equal titer of viruses. One day later, the viral
medium were replaced with fresh medium. Two days after the infection
the secondary MEF cells were seeded on 3wells with feeder layer, and
over-expression of the reprogramming factors were induced by adding
1µg/ml of Doxycycline to the medium. After 15 days, the number of
iPS colonies was compared.
8.13 qRT-PCR and List of the qPCR
primers
As it has been previously published [178], to do qRT-PCR RNA was
extracted by QIAGEN RNeasy mini kit. After measuring the concen-
trations, RNA was treated with 2U turbo DNase Ambion for about 30
min. Then DNase was inactivated according to the manual, and cDNA
was synthesized by Takara PrimeScript RT Master Mix (Perfect Real
Time) in 20µl. Real-time PCR was carried out by ABI7500 using ABI
SYBR green master mix. The thermal condition of the PCR was as
follows: 95 ◦C 10 min, 95 ◦C 15 sec, 60 ◦C 30 sec, 72 ◦C 30 sec. Melt
curve analysis was then used as a test of specificity. The primer se-
quences for the amplification of the targets were as follows:
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primer name sequence (5’-3’)
Nup210-F ATGTGGTTGAAGCCGGATAC
Nup210-R AAAACTCAGCAGGAAGCACAG
Slug-F ATGCCCAGTCTAGGAAATCG
Slug-R AGTGTGAGTTCTAATGTGTCCTTG
Snail-F CGGATGTGAAGAGATACCAGTG
Snail-R GAAGATGCCAGCGAGGATG
Ecad-F CAGTGGTCTTTCAGCTCCTTC
Ecad-R AAGGCACAGTTTATATCTCAGCA
Epcam-F TCTGGCACTGCTAACTGGTAC
Epcam-R CTTTCAGATAGGGTGTTGGATAG
ActB-F ACAGGATGCAGAAGGAGATTAC
ActB-R TAAAACGCAGCTCAGTAACAGTC
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Appendices
A.1 Abbreviations
Abbreviation Description
2iL 2i medium plus LIF
5hmC 5-hydroxymethylcytosine
5mC 5-methylcytosine
BP Biological Process
BAF Brg-Associated Factors
CC Cellular Compartment
ChIP-MS Chromatin Immuno-Precipitation with Mass Spectrometry
ChAP-MS Chromatin Affinity purification with Mass Spectrometry
ChEP Chromatin Enrichment for Proteomics
ChIP Chromatin Immuno-Precipitation
ChroP Chromatin Proteomics
EGC Embryonic Germ Cells
ESC Eembryonic Stem Cells
ER Endoplasmic Reticulum
GO Gene Ontology
GLFG glycine-leucine-phenylalanine-glycine domain
HDAC Histone Deacetylases
HPA Human Proteim Atlas
iPSC Induced Pluripotent Stem Cells
ICM Inner-Cell Mass
ICP Interphase Chromatin Probability
MET Mesenchymal to Epithelial Transition
MNase Micrococcal Nuclease
mChIP modified Chromatin Immno-Precipitation
MF Molecular Function
MAB Monoclonal Antibody
MCCP MultiClassifier Combinatorial Proteomics
Continued on next page
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Abbreviation Description
NSE Non-Super-Enhancer
OSN Oct4, Sox2 and Nanog
OSKM Oct4, Sox2, Klf4, Myc
PRC1 Polycomb Repressive Complex 1
PRC2 Polycomb Repressive Complex 2
PGC Primordial Germ Cells
PICh Proteomics of Isolated Chromatin fragments
Pol II RNA polymerase 2
SICAP Selective Isolation of Chromatin-Associated Proteins
SE Super-Enhancer
TAP Tandem Affinity Purification
TIGR Targeted Isolation of Genomic Regions
TdT Terminal deoxynucleotidyl transferase
TAL Transcription Activator-Like
TF Transcription Factors
TE Trophectoderm
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A.2 Supplementary Tables
Please find the enclosed CD for the following supplementary tables:
• Supplementary Table 3.1:
Chromatin composition of the mouse ESCs
• Supplementary Table 3.2:
Immuno-staining of some proteins enriched by SICAP
• Supplementary Table 3.3:
Comparing chromatin protein composition, full proteome
and transcriptome between 2i and serum conditions
• Supplementary Table 4.1:
Nanog ChIP-SICAP in comparison with no-antibody ChIP-
SICAP
• Supplementary Table 4.2:
Comparing Oct4, Sox2, Nanog and E-cadherin ChIP-
SICAP between 2i and serum conditions
• Supplementary Table 4.3:
The overlap of Trim24 binding sites with OSN on non-
super-enhancers, and super-enhancers
• Supplementary Table 4.4:
Suz12 ChIP-SICAP
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• Supplementary Table 4.5:
Dazl ChIP-SICAP
• Supplementary Table 5.1:
TIGR using Nanog-519, Nanog-453 and the scramble
probe
• Supplementary Table 5.2 :
TIGR using Nanog-519 in 2i and serum conditions
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